celecoxib and rofecoxib

celecoxib has been researched along with rofecoxib in 509 studies

Research

Studies (509)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	24 (4.72)	18.2507
2000's	437 (85.85)	29.6817
2010's	42 (8.25)	24.3611
2020's	6 (1.18)	2.80

Authors

Authors	Studies
Black, WC; Brideau, C; Chan, CC; Charleson, S; Chauret, N; Claveau, D; Ethier, D; Gordon, R; Greig, G; Guay, J; Hughes, G; Jolicoeur, P; Leblanc, Y; Nicoll-Griffith, D; Ouimet, N; Prasit, P; Riendeau, D; Visco, D; Wang, Z; Xu, L	1
Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R; Gresser, M; Guay, J; Kargman, S; Kennedy, B; Leblanc, Y; Léger, S; Mancini, J; O'Neill, GP; Ouellet, M; Percival, MD; Perrier, H; Prasit, P; Riendeau, D; Rodger, I; Wang, Z; Zamboni, R	1
Boyce, S; Brideau, C; Chan, CC; Charleson, S; Gordon, R; Grimm, E; Guay, J; Leblanc, Y; Léger, S; Li, CS; Prasit, P; Riendeau, D; Roy, P; Visco, D; Wang, Z; Webb, J; Xu, LJ	1
Black, WC; Brideau, C; Chan, CC; Charleson, S; Claveau, D; Cromlish, WA; Gauthier, JY; Gordon, R; Greig, G; Grimm, E; Guay, J; Lau, CK; Li, CS; Prasit, P; Riendeau, D; Thérien, M; Visco, DM; Wong, E; Xu, L	1
Brideau, C; Chan, CC; Charleson, S; Cromlish, WA; Ethier, D; Gauthier, JY; Gordon, R; Guay, J; Kargman, S; Lau, CK; Li, CS; Prasit, P; Riendeau, D; Thérien, M; Visco, DM; Xu, L	1
Byun, YJ; Choi, JK; Chung, S; Ha, JY; Kim, JK; Kim, JY; Lee, CH; Lim, KM; Noh, MS; Shin, SS	1
Habeeb, AG; Knaus, EE; Praveen Rao, PN	1
Crespo, MI; Feixas, J; Godessart, N; Jiménez, JM; Puig, C; Soca, L	1
Aparici, M; Borràs, L; Cabré, F; Cabré, M; Carabaza, A; García, ML; González, G; Mauleón, D; Palomer, A; Pascual, J	1
Cabré, F; Campos, J; Entrena, A; Espinosa, A; Gallo, MA; García, L; Mauleón, D; Palomer, A; Pascual, J; Trujillo, MA	1
Haruta, J; Hashimoto, H; Imamura, K; Wakitani, K	1
Knaus, EE; Rahim, MA; Rao, PN	1
Black, WC; Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Gordon, R; Grimm, EL; Hughes, G; Leger, S; Li, CS; Prasit, P; Riendeau, D; Thérien, M; Wang, Z; Xu, LJ	1
Misra, P; Nagabelli, M; Pal, M; Rao Casturi, S; Rao Kalleda, S; Rao Veeramaneni, V; Rao Yeleswarapu, K	1
Amini, M; Habeeb, AG; Knaus, EE; Li, H; Rao, PN	1
Borst, P; de Haas, M; Kuil, A; Reid, G; van der Heijden, I; Wielinga, P; Wijnholds, J; Zelcer, N	1
Alfón, J; Almansa, C; Bartrolí, J; Carceller, E; Cavalcanti, FL; de Arriba, AF; Escamilla, I; García-Rafanell, J; Gómez, LA; Merlos, M; Miralles, A; Soliva, R	1
Casturi, SR; Gopalakrishnan, B; Kalleda, S; Madan, M; Malde, A; Mamidi, NV; Mullangi, R; Padakanti, S; Pal, M; Pattabiraman, VR; Vanguri, A; Yeleswarapu, KR	1
Amini, M; Habeeb, AG; Knaus, EE; Li, H; Praveen Rao, PN	1
Earl, RA; Ezawa, M; Fang, X; Garvey, DS; Gaston, RD; Janero, DR; Khanapure, SP; Letts, LG; Marek, P; Martino, A; Murty, M; Shumway, M; Tam, SW; Trocha, M; Young, DV	1
Byun, Y; Choi, JK; Choi, YH; Chung, S; Jeong, YS; Kim, JK; Kim, JY; Koh, HJ; Lee, KW; Lim, KM; Moh, JH; Noh, MS; Oh, YI; Park, YH; Shin, SS	1
Knaus, EE; Rao, PN; Uddin, MJ	2
Augustyniak, M; Bandarage, UK; Earl, RA; Ellis, JL; Garvey, DS; Janero, DR; Letts, LG; Martino, AM; Murty, MG; Ranatunge, RR; Richardson, SK; Schroeder, JD; Shumway, MJ; Tam, SW; Trocha, AM; Young, DV	1
Knaus, EE; McDonald, R; Rahim, MA; Rao, PN; Uddin, MJ	1
Beswick, P; Bingham, S; Bountra, C; Brown, T; Browning, K; Campbell, I; Chessell, I; Clayton, N; Collins, S; Corfield, J; Guntrip, S; Haslam, C; Lambeth, P; Lucas, F; Mathews, N; Murkit, G; Naylor, A; Pegg, N; Pickup, E; Player, H; Price, H; Stevens, A; Stratton, S; Wiseman, J	1
Knaus, EE; McDonald, R; Praveen Rao, PN; Uddin, MJ	1
Earl, RA; Garvey, DS; Janero, DR; Letts, LG; Martino, AM; Murty, MG; Ranatunge, RR; Richardson, SK; Schwalb, DJ; Young, DV; Zemtseva, IS	1
Charlier, C; Durant, F; Goossens, JF; Goossens, L; Hénichart, JP; Houssin, R; Pommery, J; Pommery, N; Taverne, T; Telliez, A	1
Knaus, EE; McDonald, R; Rao, PN; Uddin, MJ	1
Anzini, M; Biava, M; Botta, M; Cappelli, A; Makovec, F; Manetti, F; Porretta, GC; Rossi, A; Sautebin, L; Vomero, S	1
Augustyniak, ME; Earl, RA; Garvey, DS; Janero, DR; Khanapure, SP; Letts, LG; Martino, AM; Murty, MG; Schwalb, DJ; Shumway, MJ; Trocha, AM; Young, DV; Zemtseva, IS	1
Byvatov, E; Franke, L; Schneider, G; Schneider, P; Steinhilber, D; Werz, O	1
Chen, QH; Knaus, EE; Rao, PN	1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Carrupt, PA; Cena, C; Chegaev, K; Fruttero, R; Gasco, A; Lazzarato, L; Marini, E; Rolando, B; Tosco, P	1
Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S	1
Abdellatif, KR; Chen, QH; Chowdhury, MA; Dong, Y; Knaus, EE	3
Kaur, S; Kumar, S; Mittal, A; Singh, P	1
Billa, VK; Boominathan, R; Gabriel, JL; Mallireddigari, MR; Pallela, VR; Reddy, EP; Reddy, MV	1
Anzellotti, P; Anzini, M; Biava, M; Botta, M; Cappelli, A; Ghelardini, C; Giordani, A; Makovec, F; Manetti, F; Norcini, M; Patrignani, P; Pergola, C; Rossi, A; Rovini, M; Sautebin, L; Vomero, S	1
Chen, CS; Chiu, HC; Gunn, JS; Kulp, SK; Schlesinger, LS; Soni, S; Yang, J	1
Beswick, PJ; Bingham, S; Bountra, C; Carter, MC; Chambers, LJ; Chessell, IP; Clayton, NM; Collins, SD; Corfield, JA; Gleave, RJ; Green, RH; Hartley, CD; Kleanthous, S; Lambeth, PF; Lucas, FS; Mathews, N; Naylor, A; Page, LW; Payne, JJ; Pegg, NA; Price, HS; Skidmore, J; Stevens, AJ; Stocker, R; Stratton, SC; Stuart, AJ; Swarbrick, ME; Wiseman, JO	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Bhardwaj, A; Singh, P	1
Basset, J; Casula, G; Cusimano, MG; Harrak, Y; Plescia, S; Pouplana, R; Pujol, MD; Raffa, D; Rosell, G	1
Dong, H; Hammock, BD; Hwang, SH; Liu, JY; Morisseau, C; Wagner, KM; Wecksler, AT	1
Katsu, T; Matoyama, M; Miyata, K; Mizushima, T; Okamoto, Y; Otsuka, M; Suemasu, S; Tanaka, K; Yamakawa, N	1
Abdellatif, KR; Chowdhury, MA; Huang, Z; Kaufman, S; Knaus, EE	1
Blobaum, AL; Crews, BC; Daniel, CM; Ghebreselasie, K; Kingsley, PJ; Liedtke, AJ; Marnett, LJ	1
Bhardwaj, A; Huang, Z; Kaur, J; Knaus, EE; Sharma, SK; Wuest, F	1
Duan, YC; Lin, ZT; Liu, GZ; Liu, HM; Wang, P; Xu, HW; Zheng, JX	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Hanaya, K; Katsu, T; Mizushima, T; Shoji, M; Sugai, T; Suzuki, K; Yamakawa, N; Yamashita, Y	1
Bonanni, D; Boschi, D; Carnovale, IM; Cena, C; Costale, A; Giraudo, A; Lolli, ML; Marini, E; Oliaro-Bosso, S; Pippione, AC; Pors, K; Sadiq, M; Zonari, D	1
Ramajayam, R	1
Asif, M; Husain, A; Iqbal, MA; Iram, F; Khan, SA	1
Banerjee, UC; Chakraborti, AK; Dave, K; Dubey, S; Garg, SK; Goyal, R; Kumar, R; Meena, VS; Purohit, P; Saha, N; Seth, K; Sharma, SS	1
Hawkey, CJ	3
Miller, JL	1
Brune, K; Hinz, B	2
Ziegler, J	1
Fung, HB; Kirschenbaum, HL	1
Gómez Rodríguez, B; Hergueta Delgado, P; Herrerías Esteban, J; Herrerías Gutiérrez, J; Ledro Cano, D; Torres Domínguez, Y	1
Ryan, PF; Schachna, L	1
Heinzl, S	1
Daniels, S; Desjardins, PJ; Kotey, P; Malmstrom, K; Seidenberg, BC	1
Houben, JJ; Liem, B	1
Rodgers, E	1
Brater, DC	1
Pascucci, RA	1
Dionne, R	1
Blain, A; Blain, H; Jeandel, C; Jouzeau, JY; Netter, P; Terlain, B; Touchon, J; Tréchot, P	1
Infante, R; Lahita, RG	1
Blondon, H	1
Malakoff, D	1
Strassels, S	1
Jeske, AH	1
Aramberry, LJ; Cesolari, JA; Esnarriaga, J; Godoy, A; Laudanno, OM; Maglione, C; Piombo, G; Rista, L; Rocaspana, A; Sambrano, JS	1
Hawkey, CJ; Jackson, LM	1
King, DS; Noble, SL; Olutade, JI	1
Oliw, E; Wollheim, FA	1
Urban, MK	1
Davis, JV; Linder, JD; Mönkemüller, KE; Wilcox, CM	1
Connelly, NR; Reuben, SS	1
Everts, B; Hedner, T; Währborg, P	1
Bhat, VB; Kiranmai, G; Madyastha, KM; Reddanna, P; Reddy, CM; Reddy, MN	1
Brooks, PM; Day, RO	1
Takanishi, GC	1
Giercksky, KE; Haglund, U; Rask-Madsen, J	1
Breedveld, FC; Cannon, GW	1
Burmester, GR; Buttgereit, F; Simon, LS	1
Sundy, JS	1
Gottlieb, S	1
Bjarnason, I; Rainsford, KD	1
Frölich, JC; Stichtenoth, DO	1
McCaffery, M; Pasero, C	1
Hersh, EV; Moore, PA	1
Aramberry, L; Cesolari, JA; Esnarriaga, J; Godoy, A; Laudanno, OM; Maglione, C; Piombo, G; Rista, L; Rocaspana, A; Sambrano, J	1
Jawad, AS	1
Gaitan, G; Herrero, JF; Mazario, J	1
Chen, C; Hsu, A; Johnson, AJ; song, X	1
Sternon, J	1
Bijlsma, JW; Lems, WF; van de Laar, MA	1
Ferencik, M; Novak, M; Rovensky, J; Rybar, I	1
García Rodríguez, LA; Patrignani, P; Patrono, C	1
Perazella, MA; Tray, K	1
Macknight, C; Rojas-Fernandez, CH	1
Bannwarth, B	1
Gotlieb, D	1
Reuben, SS	2
Mejza, F; Nizankowska, E	1
Wasko, MC; Wildy, KS	1
Chaiton, A; Nguyen, A	1
FitzGerald, GA; Patrono, C	1
Swaak, AJ; Theunissen, DJ	1
Comarow, A	1
Adler, J	1
Gorman, C	1
Turnheim, K	1
Nakamura, H	1
Zeidler, H	1
Cleland, LG; James, MJ; Penglis, PS; Stamp, LK	1
Arellano, FM; Lejkowith, J; Reynolds, MW; Whelton, A; Zhao, SZ	1
Peretz, A	1
Browning, RA; Burgess, FW	1
Schnitzer, TJ	1
Kessenich, CR	1
Buffum, JC; Buffum, M	1
Butterfield, JH; Kelkar, PS; Teaford, HG	1
Deray, G	1
Ouellet, M; Percival, MD; Riendeau, D	1
Fleming, M	1
Dixon, ME; Geba, GP; Polis, AB; Schnitzer, TJ; Weaver, AL	1
Shi, G	1
Killen, JP	1
Beitz, J; Bonnel, RA; Brinker, AD; Karwoski, CB; Weaver, J	1
McColl, GJ	1
Bonnel, RA; Brinker, AD; Feight, AG; Nourjah, P	1
Krüger, K	1
Rocamora Batalla, M; Vallano Ferraz, A	1
Alegre Del Rey, EJ	1
Nervetti, A; Rioda, WT	1
Wiholm, BE	1
Capriotti, T	1
FitzGerald, GA	2
Mukherjee, D	2
Gumired, K; Patti, R; Phillips, PC; Reddanna, P; Reddy, CD; Sutton, LN	1
Fenn, CG	1
Berger, MY; Bierma-Zeinstra, SM; Bohnen, AM; Thomas, S	1
Henderson, P	1
Cereza, G; Laporte, JR; Pedrós, C	1
Day, RO; Graham, GG; Graham, RI	1
Schoors, D	1
Chandra, A; Nair, MG; Schutzki, R; Seeram, NP	1
Chen, CS; Johnson, AJ; Kulp, SK; Lin, HP; Song, X; Tseng, PH; Yang, YT	1
Eitner, F; Floege, J; Janssen, U; Kerjaschki, D; Kitahara, M; Kunter, U; Matsui, K; Ostendorf, T; Westenfeld, R	1
Pomp, E	1
Paakkari, I	1
Sharma, RA	1
Crofford, LJ	1
Berenbaum, F	1
Hardy, KJ; McMurray, RW	1
Loftus, EV; Mahadevan, U; Sandborn, WJ; Tremaine, WJ	1
Arguelles, LM; Burke, TA; Flowers, N; Pettitt, D; Wolfe, F	1
Clegg, DO; Silas, S	1
Clifford, LJ; Dewitt, DL; Nair, MG; Rana, J	1
Tomasová-Studýnková, J	1
Crofford, LJ; Gupta, S	1
Ahmad, SR; Beitz, J; Brinker, A; Chen, M; Kortepeter, C	1
Bristol, S; Burke, TA; May, C; Osterhaus, JT; Wentworth, C; Whelton, A	1
Wooltorton, E	1
Boers, M	1
Budenholzer, BR	1
Anderson, GM; Juurlink, DN; Mamdani, M	1
Stover, RR	1
Brune, K; Gertz, BJ; Gottesdiener, KM; Holmes, GB; Kalyani, RN; Lasseter, KC; Laurenzi, M; Malice, MP; Redfern, KJ; Schwartz, JI; Vandormael, K	1
Bianchi, M; Broggini, M	2
Peres, MF; Silberstein, SD	1
Lednicer, D	1
Atkinson, HG	1
Hochberg, MC; Strand, V	1
Howes, LG; Krum, H	1
Jones, R	1
Anderson, GM; Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Mamdani, M; Naglie, G; Rochon, PA	1
Pfeifer, M	1
Arbogast, PG; Daugherty, JR; Griffin, MR; Hall, K; Ray, WA; Stein, CM	1
Arakawa, T; Kanatsu, K; Kato, S; Ogawa, Y; Okayama, M; Takeuchi, K; Watanabe, T	1
Cryer, B; Kelley, CL; Kelly, KC; Weideman, RA	1
Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB	1
de Lima, OM; Dicay, M; Distrutti, E; Fiorucci, S; Ma, L; McKnight, W; Mencarelli, A; Morelli, A; Palazzetti, B; Romano, M; Wallace, JL	1
Bakhle, YS; Chaves, CT; Ferreira-Alves, DL; Francischi, JN; Lima, AS; Moura, AC; Rocha, OA	1
Burke, TA; Henderson, SC; von Allmen, H; Whelton, A; Zhao, SZ	2
Sonnenblick, EH	1
Håkansson, J	1
Wollheim, FA	1
Anderson, G; Laupacis, A; Mamdani, M; Rochon, P	1
van der Bijl, P	1
Cutts, C; LaCaze, A; Tett, S	1
Hochberg, MC	2
Fricke, JR; Kotey, P; Kress, B; Malmstrom, K; Morrison, B	1
Chen, CS; Lin, HP; Marquez, VE; Song, X; Yan, S; Young, DC; Zhu, J	1
Hutchins, B; Hutchins, V	1
Calixto, JB; Pinheiro, RM	1
Lane, S; Linley, W; Maskrey, N; McQuade, C; Micklewright, R; Thompson, F	1
Devière, J	1
Anderson, GM; Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Mamdani, M; Naglie, G; Rochon, P	1
Harley, C; Wagner, S	2
Hisel, TM; Johnson, DL; Phillips, BB	1
Issioui, T; Klein, KW; Watcha, MF; White, PF	1
Almansa, C; Kalko, SG; Luque, FJ; Orozco, M; Soliva, R	1
Gibofsky, A	1
Gyr, N; Lehmann, FS	1
Amouri, A; Ben Ammar, A; Ben Mami, N; Chaabouni, H; Cheikh, I; Kchaou, M; Ouerghi, H	1
Alderman, M; Sperling, R; Weaver, A	1
Becker, RV; Burke, TA; McCoy, MA; Trotter, JP	1
Dulai, GS; Gralnek, IM; Spiegel, BM; Targownik, L	1
Krahn, M; Maetzel, A; Naglie, G	1
Alagöl, A; Arar, C; Colak, A; Gemlik, I; Karamanlioğlu, B; Süt, N	1
Grewe, M; Kruse, R; Ruzicka, T	1
Giles, LG; Muller, R	1
Brune, K; Fromm, MF; Hinz, B; Rau, T; Werner, D; Werner, U	1
Bardou, M; Barkun, AN; Rahme, E; Toubouti, Y	1
Egan, M; Morreale, AP; Plowman, BK; Schaefer, MG	1
Hegazi, RA; Kandil, HM; Mady, HH; Melhem, MF; Mohi, M; Sepulveda, AR	1
Burnier, M; Chiolero, A; Maillard, MP	1
Burke, TA; Goldstein, JL; MacDonald, TM; Morant, SV; Pettitt, D	1
Ansani, NT; McKaveney, TP; Towers, AL; Verrico, MM; Weber, RJ	1
Collantes-Estevez, E; Fernandez-Perez, C	1
Boehncke, WH; Gibbs, BF	1
Fernández, C; West, PM	1
Horn, FE; Kerr, SJ; Mant, A; McGeechan, K; Sayer, GP	1
Boldogh, I; Gessell-Lee, DL; Olano, JP; Peterson, JW; Popov, VL	1
Ducruet, T; Lavoie, F; Moride, Y; Rochon, S	1
Burke, TA; Dieleman, JP; Goldstein, JL; Lee, F; Sturkenboom, MC; Tangelder, MJ	1
Laskin, B; Pashos, C; Peña, B; Stephens, J; Wong, J	1
Camici, G; Fiedler, M; Fratton, A; Gay, RE; Gay, S; Hellermann, JP; Hermann, M; Hurlimann, D; Lüscher, TF; Neidhart, M; Ruschitzka, F; Tanner, FC; Thiery, J	1
Oviedo, JA; Wolfe, MM	1
Fort, JG; Gibofsky, A; McKenna, F; Williams, GW	1
Dickerson, LM; Nietert, PJ; Ornstein, SM; Rothenberg, RJ	1
Bhatia, S; Seedher, N	1
Clark, DW; Coulter, DM; Savage, RL	1
Wright, JM	1
Abdel-Salam, OM; Arbid, MS; Baiuomy, AR	1
Burian, M; Geisslinger, G	1
Lu, S; Mosholder, AD; Phelan, KM	1
Mastalerz, L; Radziszewski, W; Setkowicz, M; Szczeklik, A; Zembowicz, A	1
Castello, JV; de Mateo, JA; Enrique, E; Malek, T; Roca, B; Rodríguez, M	1
Emkey, R; Jordan, D; Kamin, M; Rosenthal, N; Wu, SC	1
Blumenthal, M; Chen, TC; Kardosh, A; Schönthal, AH; Wang, WJ	1
Arber, N; Choen-Noyman, E; Deutsch, V; Dvory-Sobol, H; Kazanov, D; Kunik, T; Liberman, E; Pick, M; Strier, L	1
Casini, A; Heine, A; Klebe, G; Kuhn, D; Scozzafava, A; Supuran, CT; Weber, A	1
Nelson, MR	1
Kong, SX; Mavros, P; Mitchell, JH; Pellissier, JM; Schnitzer, TJ; Straus, WL; Watson, DJ	1
Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ	1
FitzGerald, GA; Mardini, IA	1
Florin, TH	1
Patrignani, P	1
Girvin, B; Johnston, GD; Rafferty, T; Stevenson, MR	1
Avorn, J; Glynn, RJ; Kiyota, Y; Levin, R; Mogun, H; Schneeweiss, S; Solomon, DH	1
Møiniche, S; Rømsing, J	1
Fricke, J; Jayawardene, S; Kellstein, D; Ott, D	1
Beitz, J; Bonnel, R; Brinker, A; Goldkind, L	1
Burke, TA; Makuch, RW; Wentworth, C; Zhao, SZ	1
Chan, VS	1
Clark, DW; Layton, D; Shakir, SA	1
Aw, J; Haas, S; Krum, H; Liew, D	1
Brunner, M; Gehrmann, M; Kremmer, E; Multhoff, G; Pfister, K; Reichle, A	1
Pettitt, D; Wolfe, F; Zhao, S	1
Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Lee, DS; Mamdani, M; Naglie, G; Rochon, PA; Stukel, TA	1
Gately, S; Li, WW	1
Chakrabarti, R; Joshi, VD; Juluri, S; Kole, L; Kumari, M; Vajja, BN	1
Bouée, S; Charlemagne, A; Fagnani, F; Lancry, PJ; Le Jeunne, P; Naudin, F; Sermet, C	1
Ehnert, C; Geisslinger, G; Grösch, S; Manderscheid, C; Niederberger, E; Schmidt, H	1
Dickman, A; Ellershaw, J	1
White, WB	1
Avorn, J; Levin, R; Schneeweiss, S; Solomon, DH	1
Lamarque, D	1
Jayr, C	2
Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B	1
Boggie, DT; Delattre, ML; Morreale, AP; Plowman, BK; Schaefer, MG; Tran, F	1
Antonicelli, L; Bilò, MB; Bonadonna, P; Crivellaro, MA; Dama, AR; Schiappoli, M; Senna, G	1
Chan, WS; Cheung, SH; Kwong, KS; Leung, SP	1
Güneş, Y; Işik, G	1
Bardou, M; Barkun, AN; Ghosn, J; Hudson, M; Rahme, E	1
Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A	1
Clark, DW; Coulter, DM	1
Lapeyre-Mestre, M; Lugardon, S; Montastruc, JL	1
Conde, J; Delgado, J; Florido, JF; López-Pascual, E; Nieto, MA; Ortega, N; Quiralte, J; Sáenz de San Pedro, B	1
Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y	1
Coupal, L; Grover, SA; Zowall, H	1
Battisti, WP; Geba, GP; Katz, NP; Kivitz, AJ; Matsumoto, AK; Polis, AB; Weaver, AL	1
Vanchieri, C	2
Couzin, J	2
Brusati, C; Cacciapuoti, M; Desirello, G; Drago, F; Rebora, A	1
Clark, DW; Coulter, DM; Donnelly, E; Kennedy, MA; Roberts, RL	1
Bouras, EP; Burton, DD; Camilleri, M; Stephens, DA; Thomforde, GM	1
Chang, IJ; Harris, RC	1
Wolfe, MM	1
Meena, S; Nagaraju, D; Rao, AR; Rao, RN	1
Bühler, N; Camici, G; Chenevard, R; Gröne, HJ; Hermann, M; Kiss, E; Lüscher, TF; Ruschitzka, F; Shaw, S	1
Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S	1
Arafa, M; El-Medany, A; Mahgoub, A; Morsi, M; Mustafa, A	1
Brabant, T; Fort, JG; Kivitz, A; Pitt, B; Simon, LS; Sowers, JR; van Ingen, H; Whelton, A; White, WB; Winer, N	1
Meyer, CH	1
Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL	1
Senior, K	1
Furberg, CD; Psaty, BM	1
Drazen, JM	1
Wadman, M	2
Boivin, JF; Ducruet, T; Moore, N; Moride, Y; Perreault, S; Zhao, S	1
Pollard, T	1
Bousquet, PJ; Demoly, P; Fontaine, C	1
Graham, DJ; Grosser, SC; Nourjah, P; Rawson, NS	1
Chang, M; Cordon-Cardo, C; Dannenberg, AJ; Du, B; Newman, RA; Patel, MI; Subbaramaiah, K; Thaler, HT; Yang, P	1
Smith, ER	1
Behan, K; Cutts, C; Tett, SE	1
Alvarez Ude, F; Fernández, MJ; Mampaso, F; Mon, C; Ortiz, M; Sánchez, R	1
Hegmann, T	1
Brinker, A; Nourjah, P	1
Laible, B	1
Gay, S; Greutert, H; Hermann, M; Lüscher, TF; Ruschitzka, F; Steffel, J; Tanner, FC	1
Diggins, DA; Fredy, J; Morrill, GB	1
Okie, S	1
Helin-Salmivaara, A; Huupponen, R; Klaukka, T; Virtanen, A	1
Evensen, S; Slørdal, L; Spigset, O	1
Chiou, CF; Ofman, JJ; Spiegel, BM	1
Harris, RE	1
Romanovsky, AA	1
Maloney, DM	1
Klotz, U	1
Thompson, CA	1
Ashton, J; Harrison-Woolrych, M; Herbison, P; McLean, R; Slattery, J	1
Handa, H; Ito, T; Kawai, S; Kusunoki, N; Sakurai, N; Suguro, T	1
Ablett, D; Kaye, R; Reuben, SS	1
Botteman, M; DeLattre, M; Gao, X; Morreale, A; Schaefer, M; Stephens, J	1
Friis, S; Johnsen, SP; Larsson, H; McLaughlin, JK; Nørgård, B; Sørensen, HT; Tarone, RE	1
Chouahnia, K; Morère, JF; Spano, JP	1
Geba, GP; Petruschke, RA; Polis, AB; Schnitzer, TJ; Weaver, AL	1
Geisslinger, G; Grösch, S; Janssen, A; Maier, TJ; Schmidt, R	1
Hudson, M; Pilote, L; Richard, H	1
Olsen, NJ	1
Brophy, JM	2
Meena, S; Nageswara Rao, R; Raghuram Rao, A	1
Epstein, RA	1
Harris, S; Kasliwal, R; Layton, D; Shakir, SA; Wilton, L	1
Alanoglu, Z; Ateş, Y; Orbey, BC; Türkçapar, AG	1
Durrieu, G; Montastruc, JL; Olivier, P	1
Abeles, AM; Abeles, M	1
Messerli, FH; Sichrovsky, T	1
Brien, JA; Day, RO; Hamama, AK; Ray, J	1
Bonnel, R; Brinker, A; Governale, L; Karwoski, C; La Grenade, L; Lee, L; Weaver, J	1
Meechan, J	1
Araujo, LF; Fernandes, Jde L; Serrano Júnior, CV; Soeiro, Ade M	1
Epstein, J; Klasser, GD	1
Holt, CI; Hutchins, MO; Pileggi, R	1
Gherardi, CR	1
Brune, K; Dormann, H; Hinz, B	1
Birbara, C; Chang, DJ; Petruschke, RA; Rodgers, A; Ruoff, G; Sheldon, E; Tershakovec, AM; Valenzuela, C	1
Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD	1
Hunsche, E; Rahme, E; Toubouti, Y	1
Chabot, I; Hunsche, E; Rahme, E; Toubouti, Y	1
Fraunfelder, FW; Mehelas, TJ; Solomon, J	1
Guo, ZR	1
Barbaud, A; Schmutz, JL; Trechot, P	1
Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW	1
Dogné, JM; Hanson, J; Pratico, D; Supuran, C	1
Calvo, N; Iversen, E; Munck, LK	1
Geisslinger, G; Tegeder, I	1
Sooriakumaran, P	1
Brophy, JM; Lévesque, LE; Zhang, B	2
Hirota, T; Ikeda, T; Inoue, S; Kawai, K; Koyama, K; Oitate, M	1
Fujita, I; Hizue, M; Kanai, Y; Matsuura, T; Murase, A; Murata, Y; Naganeo, R; Nakao, K; Okumura, T; Sakakibara, A	1
Nelson, NJ	1
Andersohn, F; Garbe, E; Schade, R; Suissa, S	1
Geisslinger, G; Grösch, S; Maier, TJ; Schiffmann, S	1
Falcone, T; Shakiba, K	1
Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Jacobsen, S; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Schramm, TK; Torp-Pedersen, C	1
Byun, J; Day, CA; Jacob, RF; Lockwood, SF; Mason, RP; McNulty, HP; Walter, MF	1
Abdi, K; Amini, M; Dehpour, AR; Ghahremani, MH; Navidpour, L; Shafaroodi, H; Shafiee, A	1
Barner, JC; Busti, AJ; Lawson, KA; Motsko, SP; Rascati, KL; Wilson, JP; Worchel, J	1
Chen, SH; Hsieh, YH; Lin, SJ	1
Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL	1
Boshier, A; Friedmann, P; Layton, D; Marshall, V; Shakir, SA	1
Furberg, CD	1
Hermann, M; Lüscher, TF	1
Akhmedov, A; Fähndrich, C; Lüscher, TF; Ruschitzka, F; Steffel, J; Tanner, FC	1
Aw, TJ; Billah, B; Krum, H; Liew, D; Morel-Kopp, MC; Schneider, HG; Tofler, GH	1
Bohn, L; Sadée, W	1
Henry, D; McGettigan, P	1
Macrì, R; Manfredi, C	1
Arana, A; Castellsague, J; Perez-Gutthann, S; Sanchez-Matienzo, D	1
Cheon, YK; Cho, YD; Han, CH; Jang, JY; Kim, BS; Kim, JH; Kim, YS; Kwon, KH; Moon, JH; Shim, CS; Song, HJ	1
Aghazadeh-Habashi, A; Harirforoosh, S; Jamali, F	1
Marwali, MR; Mehta, JL	1
Broich, K; Heim, HK	1
Ji, JD; Lee, YH; Song, GG	1
de Francischi, JN; de Menezes, GB; dos Reis, WG; Duarte, ID; Santos, JM	1
Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS	1
Deray, G; Montalescot, G; Sibilia, J	1
Deray, G; Héloire, F; Valat, JP	1
Kong, SX; LeLorier, J; Rahme, E; Toubouti, Y; Watson, DJ	1
Lynch, PM	2
Boschi, D; Cena, C; Del Grosso, E; Di Stilo, A; Fruttero, R; Gasco, A; Lazzarato, L; Moro, S	1
Jugdutt, BI	1
Nedjar, H; Rahme, E	1
Macedo, GM; Medeiros, BA; Nobre-e-Souza, MA; Palheta-Junior, RC; Santos, AA; Santos, CL; Souza, MH; Troncon, LE	1
Tabrizchi, R	1
Amouretti, M; Bégaud, B; Bénichou, J; Blin, P; Depont, F; Droz, C; Fourrier, A; Merlière, Y; Moore, N; Moride, Y; Sturkenboom, M; Velo, GP	1
Hudson, M; Pilote, L; Rahme, E; Richard, H	1
Ashcroft, DM; Chen, LC	1
Barden, CA; Chandler, HL; Colitz, CM; Kusewitt, DF; Lu, P	1
Alshafie, GA; Beebe-Donk, J; Harris, RE	1
Hasinoff, BB; Patel, D; Wu, X	1
Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS	1
Cheng, Y; Ding, G; Huang, H; Sun, W; Tao, J; Zhang, Y	1
Brownstein, JS; Kohane, IS; Mandl, KD; Sordo, M	1
Arguelles, J; Cobo, J; Costales, M; de Carlos, F; Garcia, MA; Perillan, C; Vijande, M	1
Geisslinger, G; Graff, J; Harder, S; Klinkhardt, U; Nüsing, RM; Seyberth, H; Skarke, C; Watzer, B	1
Andrade, SE; Boudreau, D; Brown, JS; Chan, KA; Davis, RL; Graham, D; Gunter, MJ; Gurwitz, JH; Herrinton, L; Kulldorff, M; Pettus, PT; Platt, R; Raebel, MA; Roblin, D; Smith, D	1
Jamieson, B; Lo, V; Strickland, C; Wall, R	1
Kazi, JU; Li, H; Soh, JW; Thompson, WJ; Weinstein, IB	1
Chen, E; Li, C; Maguluri, S; Recchia, FM	1
Leufkens, HG; Parkinson, J; Persson, I; Smeeth, L; van Staa, TP	1
Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J	1
Han, P; Henry, D; Jones, L; McGettigan, P; Whitaker, D	1
Bagheri, H; Grolleau, S; Lapeyre-Mestre, M; Montastruc, JL; Sommet, A	1
Banerjee, S; Brilakis, ES; Cryer, B; Cunningham, F; Harford, WV; Kazi, S; Kelly, KC; Little, BB; Warner, JJ; Weideman, RA	1
Gilbert, AL; Pratt, N; Ramsay, E; Roughead, EE	1
Criswell, LA; Hersh, AO; Julian, L; Katz, P; Panopalis, P; Trupin, L; von Scheven, E; Yazdany, J; Yelin, E	1
Simon, LS; White, WB	1
Castellsague, J; Gimeno, V; Hoffman, CC; Holick, CN; Perez-Gutthann, S; Stang, MR	1
Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C	1
Ali, F; Birdsey, GM; Dumont, O; Evans, PC; Hamdulay, SS; Haskard, DO; Mason, JC; Wang, B; Wheeler-Jones, CP	1
Hsiao, FY; Huang, WF; Tsai, YW	1
Einarsdottir, R; Gudbjornsson, B; Halldorsson, M; Johannsson, M; Sigvaldason, H; Thorgeirsson, G; Thorsteinsson, SB; Zoega, H	1
Adrahtas, A; Bertucci, MC; Cheung, RY; Krum, H; Ma, JY; Wang, BH	1
Elliott, WJ	1
Ashok, V; Dash, C; Rohan, TE; Sprafka, JM; Terry, PD	1
Groves, KE; MacKinnon, NJ; Schellinck, T; Sketris, I	1
Honjo, H; Iwamoto, K; Uwai, Y	1
Bäck, M; Ingelsson, E; Yin, L	1
Lafrance, JP; Morin, S; Nedjar, H; Rahme, E; Roussy, JP	1
Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM	1
Higuchi, M; Ji, B; Kaneko, H; Kumata, K; Minamihisamatsu, T; Ono, M; Onoe, H; Seki, C; Shukuri, M; Suhara, T; Tokunaga, M; Zhang, MR	1
Grabosch, SM; Helm, CW; Shariff, OM; Wulff, JL	1
Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y	1
Dulski, M; Grzybowska, K; Jurkiewicz, K; Knapik, J; Paluch, M; Rams-Baron, M; Ratuszna, A; Sawicki, W; Smolka, W; Wojnarowska, Z	1
Kittanamongkolchai, W; Srivali, N; Ungprasert, P	1
Barozzi, N; Peeters, GM; Tett, SE	1
Balbontín-Ayala, F; Cañigral, A; Carlos, Fd; Cobo, T; Fernández-González, FJ; Fernández-Vázquez, JP; Gonzalo-Orden, JM; Sánchez-Lasheras, F; Vega, JA	1
Matteson, EL; Thongprayoon, C; Ungprasert, P	1
Hansen, SH; Skonberg, C; Syed, M	1
Malkowski, MG; Orlando, BJ	1
Carsons, SE; De Leon, J; Gomolin, IH; Kasselman, LJ; Littlefield, MJ; Reiss, AB; Voloshyna, I	1
Doshi, P; Godlee, F	1
Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM	1
Gislason, G; Sondergaard, KB	1
Aghazadeh-Habashi, A; Asghar, W; Jamali, F	1
Grabosch, SM; Helm, CW; Shariff, OM	1
Al-Khrasani, M; Balogh, M; Bató, E; Bihari, Z; Brenner, GB; Ferdinandy, P; Giricz, Z; Gyires, K; Helyes, Z; Hutka, B; Juhász, J; Kemény, Á; László, SB; László, T; Lázár, B; Makkos, A; Ostorházi, E; Szabó, D; Tiszlavicz, L; Zádori, ZS	1
Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C	1
Araújo, PHF; Campos, JM; da Cruz, JN; de Lima, LR; Espejo-Román, JM; Ferreira, EFB; Macêdo, WJC; Ramos, RS; Santos, CBR; Silva, SG	1
Jiang, C; Ma, L; Wang, H; Zhang, L	1
Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K	1
Hjemdahl, P; Stiller, CO	1
Bai, H; Hu, T; Li, Y; Liu, CJ; Liu, F; Tang, W; Wang, D; Yin, L; Yin, X	1

Reviews

125 review(s) available for celecoxib and rofecoxib

Article	Year
Medicinal chemistry of vicinal diaryl scaffold: A mini review. European journal of medicinal chemistry, 2019, Jan-15, Volume: 162 Topics: Carbonic Anhydrase IV; Chemistry, Pharmaceutical; Cyclooxygenase 2 Inhibitors; Drug Discovery; Humans; Hydrocarbons, Aromatic; Structure-Activity Relationship	2019
Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore. European journal of medicinal chemistry, 2019, Jun-01, Volume: 171 Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Molecular Structure	2019
[Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances]. Wiener klinische Wochenschrift, 1999, Feb-12, Volume: 111, Issue:3 Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Treatment Outcome	1999
Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clinical therapeutics, 1999, Volume: 21, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Interactions; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	1999
COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs. The Medical journal of Australia, 1999, Aug-16, Volume: 171, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Humans; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	1999
[Topical pharmacology. COX-2 inhibitors]. Medizinische Monatsschrift fur Pharmazeuten, 1999, Volume: 22, Issue:10 Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	1999
Treating pain with COX-2 inhibitors. The Nurse practitioner, 1999, Volume: 24, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Costs; Drug Interactions; Female; Humans; Lactones; Pain; Pregnancy; Pyrazoles; Sulfonamides; Sulfones	1999
Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. The American journal of medicine, 1999, Dec-13, Volume: 107, Issue:6A Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Kidney; Lactones; Meloxicam; Membrane Proteins; Nabumetone; Natriuresis; Nephritis, Interstitial; Potassium; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Renal Circulation; Sodium; Sulfonamides; Sulfones; Thiazines; Thiazoles	1999
[Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives]. Presse medicale (Paris, France : 1983), 2000, Feb-12, Volume: 29, Issue:5 Topics: Adult; Age Factors; Aged; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Child; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Female; Humans; Lactones; Male; Mice; Mice, Transgenic; Neuroprotective Agents; Oxidative Stress; Pregnancy; Prostaglandins; Pyrazoles; Sulfonamides; Sulfones; Time Factors	2000
Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs. Geriatrics, 2000, Volume: 55, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Male; Middle Aged; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides; Sulfones	2000
COX-2 inhibitors and dental pain control. The Journal of the Greater Houston Dental Society, 1999, Volume: 71, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Contraindications; Cyclooxygenase Inhibitors; Facial Pain; Female; Humans; Lactones; Pain, Postoperative; Pregnancy; Pyrazoles; Sulfonamides; Sulfones; Toothache	1999
COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages? Drugs, 2000, Volume: 59, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etodolac; Humans; Lactones; Meloxicam; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles	2000
Cyclooxygenase-2 enzyme inhibitors: place in therapy. American family physician, 2000, Jun-15, Volume: 61, Issue:12 Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Bleeding Time; Blood Platelets; Celecoxib; Cyclooxygenase Inhibitors; Drug Interactions; Duodenal Ulcer; Humans; Lactones; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; United States	2000
[New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results]. Lakartidningen, 2000, Jun-14, Volume: 97, Issue:24 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Treatment Outcome	2000
COX-2 specific inhibitors offer improved advantages over traditional NSAIDs. Orthopedics, 2000, Volume: 23, Issue:7 Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytokines; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Quality of Life; Sulfonamides; Sulfones	2000
COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs. Clinical rheumatology, 2000, Volume: 19, Issue:5 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Molecular Structure; Peroxidases; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Sulfones	2000
Are rofecoxib and celecoxib safer NSAIDS? Drug and therapeutics bulletin, 2000, Volume: 38, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2000
Selective inhibitors of COX-2--are they safe for the stomach? Scandinavian journal of gastroenterology, 2000, Volume: 35, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Stomach; Stomach Ulcer; Sulfonamides; Sulfones	2000
Efficacy of cyclooxygenase-2-specific inhibitors. The American journal of medicine, 2001, Feb-19, Volume: 110 Suppl 3A Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Research Design; Sulfonamides; Sulfones; Treatment Outcome	2001
Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. The American journal of medicine, 2001, Feb-19, Volume: 110 Suppl 3A Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Gastric Mucosa; Gastrointestinal Diseases; Humans; Incidence; Isoenzymes; Lactones; Membrane Proteins; Patient Selection; Practice Guidelines as Topic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2001
COX-2 inhibitors in rheumatoid arthritis. Current rheumatology reports, 2001, Volume: 3, Issue:1 Topics: Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Digestive System; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Treatment Outcome; United States	2001
COX-2 inhibitors and the gastrointestinal tract. Gut, 2001, Volume: 48, Issue:4 Topics: Animals; Aspirin; Celecoxib; Cyclooxygenase 2; Drug Interactions; Humans; Intestinal Mucosa; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rodentia; Sulfonamides; Sulfones	2001
[Therapy with preferential and specific COX-2 inhibitors]. Der Internist, 2001, Volume: 42, Issue:3 Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Meloxicam; Membrane Proteins; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Thiazines; Thiazoles	2001
Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. Journal of the American Dental Association (1939), 2001, Volume: 132, Issue:4 Topics: Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Contraindications; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dental Care; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Safety; Sulfonamides; Sulfones	2001
[The coxibs, third generation anti-inflammatories]. Revue medicale de Bruxelles, 2001, Volume: 22, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Costs; Drug Interactions; Humans; Isoenzymes; Lactones; Membrane Proteins; Patient Selection; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2001
[Safety of specific cyclo-oxygenase 2 inhibitors]. Nederlands tijdschrift voor geneeskunde, 2001, Jun-02, Volume: 145, Issue:22 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Humans; Incidence; Lactones; Netherlands; Peptic Ulcer; Prospective Studies; Pyrazoles; Sulfonamides; Sulfones	2001
Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs. Bratislavske lekarske listy, 2001, Volume: 102, Issue:3 Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxygenase Inhibitors; Cytokines; Enzyme Inhibitors; Humans; Inflammation; Inflammation Mediators; Lactones; Neurofibrillary Tangles; Pyrazoles; Sulfonamides; Sulfones	2001
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. The Journal of clinical investigation, 2001, Volume: 108, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Dinoprostone; Epoprostenol; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Incidence; Intestinal Mucosa; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Randomized Controlled Trials as Topic; Substrate Specificity; Sulfonamides; Sulfones; Thromboembolism; Thromboxane A2; Treatment Outcome	2001
Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. The American journal of medicine, 2001, Volume: 111, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Renal Insufficiency; Sulfonamides; Sulfones	2001
[COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?]. Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:4 Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Duodenal Ulcer; Gastrointestinal Diseases; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Stomach Ulcer; Sulfonamides; Sulfones	2001
[Selective cyclooxygenase 2 inhibitors (COX-2)]. Postepy higieny i medycyny doswiadczalnej, 2001, Volume: 55, Issue:2 Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Inflammation; Isoenzymes; Lactones; Meloxicam; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles	2001
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis. Hand clinics, 2001, Volume: 17, Issue:2 Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Methotrexate; Osteoarthritis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfasalazine; Sulfonamides; Sulfones	2001
Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs? Canadian family physician Medecin de famille canadien, 2001, Volume: 47 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Peptic Ulcer; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2001
The coxibs, selective inhibitors of cyclooxygenase-2. The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Isoenzymes; Kidney; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Treatment Outcome	2001
COX-1 and COX-2 inhibitors. Best practice & research. Clinical gastroenterology, 2001, Volume: 15, Issue:5 Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2001
[Coxibs: cyclooxygenase-2 inhibitors]. Wiener klinische Wochenschrift, 2001, Aug-16, Volume: 113, Issue:15-16 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Gastric Mucosa; Humans; Isoenzymes; Kidney; Lactones; Membrane Proteins; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones	2001
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 118, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Fever; Hemorrhage; Humans; Isoenzymes; Kidney Diseases; Lactones; Membrane Proteins; Pain; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2001
COX-2 inhibition and thrombotic tendency: a need for surveillance. The Medical journal of Australia, 2001, Aug-20, Volume: 175, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Female; Gastrointestinal Diseases; Humans; Lactones; Middle Aged; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Venous Thrombosis	2001
[COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?]. Revue medicale de Bruxelles, 2001, Volume: 22, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Belgium; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Humans; Isoenzymes; Lactones; Membrane Proteins; Patient Selection; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Safety; Sulfonamides; Sulfones; Treatment Outcome	2001
Cyclo-oxygenase 2 inhibitors: an important new drug classification. Pain management nursing : official journal of the American Society of Pain Management Nurses, 2001, Volume: 2, Issue:1 Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Forecasting; Humans; Inflammation; Isoenzymes; Lactones; Membrane Proteins; Pain; Patient Selection; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2001
Nonsteroidal anti-inflammatory drugs in the elderly. Pain management nursing : official journal of the American Society of Pain Management Nurses, 2000, Volume: 1, Issue:2 Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Decision Making; Humans; Lactones; Nursing Care; Patient Education as Topic; Pyrazoles; Sulfonamides; Sulfones	2000
Arthritis. Should you be taking a COX-2 inhibitor? Harvard health letter, 2001, Volume: 27, Issue:1 Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Myocardial Infarction; Patient Education as Topic; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2001
COX-2 inhibitors: no pain, no heart gain? Harvard heart letter : from Harvard Medical School, 2001, Volume: 12, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2001
Pharmacological therapies for the treatment of osteoarthritis. The Medical journal of Australia, 2001, 11-19, Volume: 175, Issue:S3 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2001
[Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives]. Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma, 2001, Volume: 72, Issue:3-4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Prostaglandins G; Pyrazoles; Rheumatic Diseases; Sulfonamides; Sulfones	2001
The new NSAIDs: cox-2 inhibitors. Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 2000, Volume: 9, Issue:6 Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Industry; Gastrointestinal Diseases; Humans; Isoenzymes; Lactones; Meloxicam; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Safety; Sulfonamides; Sulfones; Thiazines; Thiazoles	2000
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochemical pharmacology, 2002, Mar-01, Volume: 63, Issue:5 Topics: Animals; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Epoprostenol; Humans; Isoenzymes; Lactones; Membrane Proteins; Platelet Activation; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Thrombosis	2002
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Current pharmaceutical design, 2002, Volume: 8, Issue:12 Topics: Acetaminophen; Analgesia; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Kidney; Lactones; Liver; Membrane Proteins; Osteoarthritis; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2002
Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut, 2002, Volume: 50 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Gastroscopy; Humans; Isoenzymes; Kidney; Lactones; Meloxicam; Membrane Proteins; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Randomized Controlled Trials as Topic; Stomach Ulcer; Sulfonamides; Sulfones; Thiazines; Thiazoles	2002
[A critical evaluation of side effect data on COX-2 inhibitors]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002, Feb-20, Volume: 122, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Peptic Ulcer; Pyrazoles; Sulfonamides; Sulfones	2002
[New anti-inflammatory analgetics--are they needed?]. Duodecim; laaketieteellinen aikakauskirja, 1999, Volume: 115, Issue:20 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Intestinal Mucosa; Isoenzymes; Kidney; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	1999
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer. QJM : monthly journal of the Association of Physicians, 2002, Volume: 95, Issue:5 Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Humans; Isoenzymes; Lactones; Membrane Proteins; Neoplasms; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2002
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use? Current opinion in rheumatology, 2002, Volume: 14, Issue:3 Topics: Arthritis; Aspirin; Cardiovascular System; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Isoenzymes; Kidney; Lactones; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2002
[New nonsteroidal antiinflammatory drugs in rheumatoid arthritis]. Annales de medecine interne, 2002, Volume: 153, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Gastric Mucosa; Humans; Lactones; Nausea; Pyrazoles; Sulfonamides; Sulfones; Treatment Outcome	2002
Cox-2 inhibitors: today and tomorrow. The American journal of the medical sciences, 2002, Volume: 323, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Research; Sulfonamides; Sulfones	2002
Considerations for the safe prescribing and use of COX-2-specific inhibitors. The Medical journal of Australia, 2002, Apr-01, Volume: 176, Issue:7 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Isoenzymes; Kidney Diseases; Lactones; Membrane Proteins; Practice Patterns, Physicians'; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2002
[Specific inhibitors of cyclooxygenase type 2] ]. Vnitrni lekarstvi, 2002, Volume: 48, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2002
An update on specific COX-2 inhibitors: the COXIBs. Bulletin on the rheumatic diseases, 2001, Volume: 50, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2001
Renal failure associated with the use of celecoxib and rofecoxib. Drug safety, 2002, Volume: 25, Issue:7 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Lactones; MEDLINE; Pyrazoles; Renal Insufficiency; Retrospective Studies; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2002
Tracing the origins of COX-2 inhibitors' structures. Current medicinal chemistry, 2002, Volume: 9, Issue:15 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Estradiol; Estrogen Antagonists; History, 20th Century; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones	2002
The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis and rheumatism, 2002, Volume: 47, Issue:4 Topics: Aged; Celecoxib; Coronary Thrombosis; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Male; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Survival Rate	2002
Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug safety, 2002, Volume: 25, Issue:12 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Susceptibility; Humans; Isoenzymes; Lactones; Membrane Proteins; Meta-Analysis as Topic; Myocardial Infarction; Product Surveillance, Postmarketing; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2002
Differences between COX-2-specific inhibitors: clinical and economic implications. The American journal of managed care, 2002, Volume: 8, Issue:15 Suppl Topics: Aged; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Costs; Female; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; United States	2002
Non-steroidal anti-inflammatory drugs in orofacial pain management--an update. SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 2002, Volume: 57, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Interactions; Dyspepsia; Facial Pain; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2002
Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective. The American journal of managed care, 2002, Volume: 8, Issue:17 Suppl Topics: Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Managed Care Programs; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quality-Adjusted Life Years; Sulfonamides; Sulfones; United States	2002
Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etodolac; Gastrointestinal Agents; Gastrointestinal Diseases; Humans; Isoenzymes; Lactones; Meloxicam; Membrane Proteins; Practice Guidelines as Topic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles	2003
Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? European journal of gastroenterology & hepatology, 2002, Volume: 14 Suppl 1 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Meloxicam; Neoplasms; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles	2002
Effect of cyclooxygenase-2 inhibitors on blood pressure. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Hypertension; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2003
Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2002, Volume: 20, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Rheumatic Diseases; Sulfonamides; Sulfones	2002
[The future of peptic ulcer disease without Helicobacter]. Praxis, 2003, Mar-19, Volume: 92, Issue:12 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Celecoxib; Child; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lactones; Male; Meta-Analysis as Topic; Osteoarthritis; Peptic Ulcer; Prevalence; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones	2003
[Selective cyclooxygenase-2 inhibitors and the digestive tract]. La Tunisie medicale, 2002, Volume: 80, Issue:8 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Gastrointestinal Neoplasms; Humans; Lactones; Pyrazoles; Stomach Ulcer; Sulfonamides; Sulfones	2002
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Chronic Disease; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Decision Support Techniques; Humans; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quality-Adjusted Life Years; Recurrence; Risk Factors; Sensitivity and Specificity; Sulfonamides; Sulfones	2003
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert opinion on drug safety, 2002, Volume: 1, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2002
Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Cyclooxygenase 2; Drug Hypersensitivity; Humans; Isoenzymes; Lactones; Membrane Proteins; Meta-Analysis as Topic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2003
The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology (Oxford, England), 2003, Volume: 42 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost of Illness; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quality of Life; Sulfonamides; Sulfones; Treatment Outcome	2003
Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us? Rheumatic diseases clinics of North America, 2003, Volume: 29, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Enzyme Inhibitors; Gastrointestinal Hemorrhage; Humans; Lactones; Misoprostol; Omeprazole; Osteoarthritis; Proton Pump Inhibitors; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2003
Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ (Clinical research ed.), 2003, Nov-22, Volume: 327, Issue:7425 Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Male; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones; Vision Disorders	2003
[Clinical pharmacology of the selective COX-2 inhibitors]. Der Orthopade, 2003, Volume: 32, Issue:12 Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones	2003
Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:11 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antimanic Agents; Celecoxib; Cyclooxygenase Inhibitors; Drug Interactions; Female; Humans; Lactones; Lithium Carbonate; Male; Middle Aged; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2003
Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. Molecular interventions, 2001, Volume: 1, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Models, Biological; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones	2001
A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta anaesthesiologica Scandinavica, 2004, Volume: 48, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Pain Measurement; Pain, Postoperative; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Treatment Outcome	2004
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy. Drug safety, 2004, Volume: 27, Issue:7 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2004
Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology. Drug safety, 2004, Volume: 27, Issue:7 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Product Surveillance, Postmarketing; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Thromboembolism	2004
Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Expert review of cardiovascular therapy, 2004, Volume: 2, Issue:2 Topics: Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dinoprostone; Disease Progression; Epoprostenol; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2004
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 7 Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epidermal Growth Factor; Epoprostenol; Humans; Interleukin-12; Isoenzymes; Lactones; Matrix Metalloproteinases; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Signal Transduction; Sulfonamides; Sulfones; Thromboxane A2; Vascular Endothelial Growth Factor A	2004
NSAIDs: gastroprotection or selective COX-2 inhibitor? Palliative medicine, 2004, Volume: 18, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Costs; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Isoenzymes; Lactones; Membrane Proteins; Palliative Care; Practice Guidelines as Topic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2004
[Analgesic effects of cyclooxygenase 2 inhibitors]. Bulletin du cancer, 2004, Volume: 91 Spec No Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Inflammation; Isoenzymes; Lactones; Membrane Proteins; Neoplasms; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2004
First and second generations of COX-2 selective inhibitors. Mini reviews in medicinal chemistry, 2004, Volume: 4, Issue:6 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2004
[Cyclooxygenase-2 inhibitors in postoperative pain management]. Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology, 2004, Volume: 16, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones	2004
Disturbance of vision by COX-2 inhibitors. Expert opinion on drug safety, 2004, Volume: 3, Issue:6 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blindness; Celecoxib; Cyclooxygenase Inhibitors; Databases, Factual; Epoprostenol; Female; Genetic Predisposition to Disease; Humans; Incidence; Lactones; Male; Middle Aged; Pyrazoles; Retinal Vessels; Scotoma; Sulfonamides; Sulfones; Vision Disorders; World Health Organization	2004
Are all COX-2 inhibitors created equal? Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Hypertension; Lactones; Pyrazoles; Sulfonamides; Sulfones	2005
[COX-2 inhibitors--one step forward and two steps back]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, Apr-07, Volume: 125, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2005
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis and rheumatism, 2005, Apr-15, Volume: 53, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Lactones; Lansoprazole; Naproxen; Omeprazole; Proton Pump Inhibitors; Pyrazoles; Rheumatology; Sulfonamides; Sulfones	2005
[Cyclooxygenase 2 inhibitors and lung carcinoma]. Bulletin du cancer, 2004, Volume: 91 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Lung; Lung Neoplasms; Membrane Proteins; Neoplasm Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2004
[Analgesic effects of cyclooxygenase 2 inhibitors]. Bulletin du cancer, 2004, Volume: 91 Suppl 2 Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Neoplasms; Pain; Pyrazoles; Sulfonamides; Sulfones	2004
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Current topics in medicinal chemistry, 2005, Volume: 5, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome	2005
An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices. Journal of pharmaceutical and biomedical analysis, 2005, Sep-15, Volume: 39, Issue:3-4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Industry; Etodolac; Etoricoxib; Lactones; Models, Chemical; Pyrazoles; Pyridines; Spectrophotometry; Sulfonamides; Sulfones; Ultraviolet Rays	2005
Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? The American journal of cardiology, 2005, Sep-15, Volume: 96, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones	2005
[Cardiovascular events: a class effect by COX-2 inhibitors]. Arquivos brasileiros de cardiologia, 2005, Volume: 85, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2005
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications. Journal (Canadian Dental Association), 2005, Volume: 71, Issue:8 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Peptic Ulcer; Pyrazoles; Sulfonamides; Sulfones; Toothache	2005
[Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases]. Yao xue xue bao = Acta pharmaceutica Sinica, 2005, Volume: 40, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Thromboxane A2	2005
Coxibs and cardiovascular side-effects: from light to shadow. Current pharmaceutical design, 2006, Volume: 12, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Isoxazoles; Lactones; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thromboxane A2	2006
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn-Schmiedeberg's archives of pharmacology, 2006, Volume: 373, Issue:1 Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Heart Failure; Hemostasis; Humans; Hypertension; Lactones; Naproxen; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazoles; Sulfonamides; Sulfones	2006
COX-2 inhibitors and the heart: are all coxibs the same? Postgraduate medical journal, 2006, Volume: 82, Issue:966 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Evidence-Based Medicine; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2006
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute, 2006, Jun-07, Volume: 98, Issue:11 Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; beta Catenin; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lactones; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Pyrazoles; Signal Transduction; Sulfonamides; Sulfones; Tumor Cells, Cultured	2006
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 2006, Oct-04, Volume: 296, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Lactones; Naproxen; Pyrazoles; Risk; Sulfonamides; Sulfones	2006
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. Thrombosis and haemostasis, 2006, Volume: 96, Issue:4 Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2	2006
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor. Thrombosis and haemostasis, 2006, Volume: 96, Issue:4 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Humans; Lactones; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thrombosis	2006
[What do we know about the cardiovascular toxicity of the NSAIDs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones	2007
Cardiovascular effects of cyclooxygenase-2 inhibitors. Current opinion in gastroenterology, 2007, Volume: 23, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Heart; Humans; Lactones; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones	2007
Clinical inquiries. Do COX-2 inhibitors worsen renal function? The Journal of family practice, 2007, Volume: 56, Issue:11 Topics: Arthritis, Rheumatoid; Celecoxib; Contraindications; Cyclooxygenase 2 Inhibitors; Humans; Kidney; Lactones; Osteoarthritis; Pyrazoles; Renal Insufficiency; Sulfonamides; Sulfones	2007
COX-2 selective inhibitors and heart health. Postgraduate medicine, 2005, Volume: 117, Issue:1 Suppl Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2005
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Current hypertension reports, 2010, Volume: 12, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones	2010
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia. The Cochrane database of systematic reviews, 2014, Apr-09, Issue:4 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Progression; Female; Humans; Induction Chemotherapy; Lactones; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms	2014
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. The Cochrane database of systematic reviews, 2014, Oct-23, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones	2014
Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis. European journal of internal medicine, 2015, Volume: 26, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Progression; Heart Failure; Humans; Lactones; Odds Ratio; Publication Bias; Sulfones	2015
Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review. Dental press journal of orthodontics, 2015, Volume: 20, Issue:5 Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Remodeling; Celecoxib; Clodronic Acid; Diclofenac; Diphosphonates; Humans; Imidazoles; Interferon-gamma; Isoxazoles; Lactones; Mice; Orthodontic Anchorage Procedures; Osteoclasts; Osteoprotegerin; Pamidronate; Rats; Resveratrol; Stilbenes; Sulfones; Tooth Mobility; Tooth Movement Techniques; Zoledronic Acid	2015
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. Stroke, 2016, Volume: 47, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprofen; Incidence; Indomethacin; Lactones; Meloxicam; Naproxen; Observational Studies as Topic; Odds Ratio; Piroxicam; Proportional Hazards Models; Stroke; Sulfones; Thiazines; Thiazoles	2016
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. The Cochrane database of systematic reviews, 2017, 08-02, Volume: 8 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Aspirin; Celecoxib; Child; Child, Preschool; Chronic Disease; Chronic Pain; Fenoprofen; Humans; Ibuprofen; Lactones; Meloxicam; Methoxsalen; Naproxen; Randomized Controlled Trials as Topic; Sulfones; Thiazines; Thiazoles	2017
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia. The Cochrane database of systematic reviews, 2018, 02-12, Volume: 2 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Progression; Female; Humans; Induction Chemotherapy; Lactones; Placebos; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms	2018
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. The Cochrane database of systematic reviews, 2020, 04-30, Volume: 4 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Dementia; Hemorrhage; Humans; Incidence; Lactones; Middle Aged; Myocardial Infarction; Naproxen; Randomized Controlled Trials as Topic; Stroke; Sulfones	2020
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. Journal of internal medicine, 2022, Volume: 292, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes	2022
Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis. BMC gastroenterology, 2023, Aug-14, Volume: 23, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Sulfones	2023

Trials

36 trial(s) available for celecoxib and rofecoxib

Article	Year
Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clinical therapeutics, 1999, Volume: 21, Issue:10 Topics: Adult; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Lactones; Male; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction	1999
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?]. Presse medicale (Paris, France : 1983), 2000, Mar-11, Volume: 29, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Duodenoscopy; Esophagoscopy; Gastric Mucosa; Gastroscopy; Humans; Ibuprofen; Lactones; Osteoarthritis; Peptic Ulcer; Placebos; Pyrazoles; Sulfonamides; Sulfones; Time Factors	2000
Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesthesia and analgesia, 2000, Volume: 91, Issue:5 Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Enzyme Inhibitors; Humans; Lactones; Middle Aged; Morphine; Pain Measurement; Pain, Postoperative; Premedication; Pyrazoles; Spinal Fusion; Sulfonamides; Sulfones	2000
Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA, 2002, Jan-02, Volume: 287, Issue:1 Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Osteoarthritis, Knee; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2002
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clinical pharmacology and therapeutics, 2002, Volume: 72, Issue:1 Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Celecoxib; Creatinine; Cyclooxygenase Inhibitors; Diet; Double-Blind Method; Electrolytes; Female; Humans; Kidney; Lactones; Male; Middle Aged; Naproxen; Potassium; Pyrazoles; Sodium; Sodium Chloride, Dietary; Sulfonamides; Sulfones	2002
Anti-hyperalgesic effects of nimesulide: studies in rats and humans. International journal of clinical practice. Supplement, 2002, Issue:128 Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Hyperalgesia; Lactones; Male; Middle Aged; Models, Animal; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones	2002
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. The American journal of cardiology, 2002, Nov-01, Volume: 90, Issue:9 Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Evaluation; Edema; Female; Heart Failure; Humans; Hypertension; Lactones; Male; North America; Osteoarthritis; Pyrazoles; Sulfonamides; Sulfones; Systole; Treatment Outcome; Weight Gain	2002
A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model. Clinical therapeutics, 2002, Volume: 24, Issue:10 Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibuprofen; Isoenzymes; Lactones; Male; Membrane Proteins; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction	2002
Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery. Anesthesia and analgesia, 2003, Volume: 96, Issue:4 Topics: Acetaminophen; Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Analgesics, Opioid; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Lactones; Male; Middle Aged; Otorhinolaryngologic Surgical Procedures; Pain Measurement; Pain, Postoperative; Patient Satisfaction; Postoperative Nausea and Vomiting; Pyrazoles; Sulfonamides; Sulfones	2003
Preoperative oral celecoxib versus preoperative oral rofecoxib for pain relief after thyroid surgery. European journal of anaesthesiology, 2003, Volume: 20, Issue:6 Topics: Adult; Analgesics, Opioid; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Female; Heart Rate; Humans; Lactones; Male; Meperidine; Pain, Postoperative; Premedication; Pyrazoles; Respiration; Sulfonamides; Sulfones; Surgical Procedures, Operative; Thyroid Gland	2003
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation. Spine, 2003, Jul-15, Volume: 28, Issue:14 Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Double-Blind Method; Exercise Therapy; Female; Follow-Up Studies; Humans; Lactones; Low Back Pain; Male; Manipulation, Spinal; Pain Measurement; Pyrazoles; Sulfonamides; Sulfones; Surveys and Questionnaires; Time Factors; Treatment Outcome	2003
Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clinical pharmacology and therapeutics, 2003, Volume: 74, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Double-Blind Method; Genotype; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Metoprolol; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2003
Interaction of rofecoxib and celecoxib with warfarin. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Jul-01, Volume: 60, Issue:13 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Female; Humans; International Normalized Ratio; Isoenzymes; Lactones; Male; Membrane Proteins; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Warfarin	2003
Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Current medical research and opinion, 2003, Volume: 19, Issue:5 Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Female; Health Status; Humans; Lactones; Logistic Models; Male; Middle Aged; Multivariate Analysis; Osteoarthritis; Pain; Patient Satisfaction; Product Surveillance, Postmarketing; Pyrazoles; Spain; Sulfonamides; Sulfones	2003
A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs, 2003, Volume: 63 Suppl 1 Topics: Adult; Aged; Analysis of Variance; Celecoxib; Double-Blind Method; Female; Humans; Knee; Lactones; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Knee; Pain; Pain Measurement; Pyrazoles; Sulfonamides; Sulfones; Time Factors	2003
Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis and rheumatism, 2003, Volume: 48, Issue:11 Topics: Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Lactones; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Severity of Illness Index; Sulfonamides; Sulfones; Treatment Outcome	2003
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Archives of dermatology, 2003, Volume: 139, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Celecoxib; Computer Graphics; Cross-Over Studies; Cyclooxygenase Inhibitors; Cysteine; Double-Blind Method; Drug Eruptions; Female; Humans; Lactones; Leukotriene E4; Leukotrienes; Male; Middle Aged; Multivariate Analysis; Naproxen; Prospective Studies; Pyrazoles; Serine Endopeptidases; Skin; Sulfonamides; Sulfones; Treatment Outcome; Tryptases; Urticaria	2003
Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. The Journal of rheumatology, 2004, Volume: 31, Issue:1 Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Combinations; Female; Humans; Lactones; Male; Middle Aged; Narcotics; Osteoarthritis; Pain; Placebos; Pyrazoles; Sulfonamides; Sulfones; Tramadol; Treatment Outcome	2004
Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. International journal of clinical practice, 2004, Volume: 58, Issue:3 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Lactones; Male; Molar, Third; Organic Chemicals; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction; Treatment Outcome	2004
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Jul-01, Volume: 61, Issue:13 Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxygenase 2; Drug Utilization Review; Endpoint Determination; Female; Hospitals, Veterans; Humans; Isoenzymes; Isoxazoles; Lactones; Male; Membrane Proteins; Osteoarthritis; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Therapeutic Equivalency	2004
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. European annals of allergy and clinical immunology, 2004, Volume: 36, Issue:6 Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Cross Reactions; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Female; Forced Expiratory Volume; Hemodynamics; Humans; Isoenzymes; Lactones; Male; Meloxicam; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Recurrence; Rhinitis, Allergic, Perennial; Single-Blind Method; Sulfonamides; Sulfones; Thiazines; Thiazoles; Urticaria	2004
Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 93, Issue:4 Topics: Adult; Aged; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Celecoxib; Cyclooxygenase Inhibitors; Dipyrone; Drug Hypersensitivity; Female; Humans; Lactones; Male; Middle Aged; Prospective Studies; Pyrazoles; Single-Blind Method; Sulfonamides; Sulfones	2004
Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. The journal of pain, 2004, Volume: 5, Issue:9 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Butanones; Celecoxib; Humans; Lactones; Nabumetone; Osteoarthritis, Knee; Pyrazoles; Sulfonamides; Sulfones; Treatment Outcome	2004
Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans. Neurogastroenterology and motility, 2004, Volume: 16, Issue:6 Topics: Adolescent; Adult; Aged; Celecoxib; Cisapride; Cyclooxygenase Inhibitors; Female; Gastric Emptying; Gastrointestinal Agents; Gastrointestinal Transit; Humans; Intestine, Small; Lactones; Male; Middle Aged; Pyrazoles; Radionuclide Imaging; Sulfonamides; Sulfones	2004
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. The Journal of rheumatology, 2005, Volume: 32, Issue:1 Topics: Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Hypertension; Lactones; Osteoarthritis; Pyrazoles; Sulfonamides; Sulfones	2005
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Archives of internal medicine, 2005, Jan-24, Volume: 165, Issue:2 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blood Pressure Determination; Celecoxib; Cyclooxygenase Inhibitors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Hypertension; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis; Probability; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; Treatment Outcome	2005
Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. The Journal of rheumatology, 2005, Volume: 32, Issue:6 Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lactones; Male; Middle Aged; Osteoarthritis, Knee; Pain; Pain Measurement; Pyrazoles; Severity of Illness Index; Sulfonamides; Sulfones; Treatment Outcome	2005
Preoperative use of selective COX-II inhibitors for pain management in laparoscopic nissen fundoplication. Surgical endoscopy, 2005, Volume: 19, Issue:9 Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Female; Fundoplication; Humans; Lactones; Laparoscopy; Male; Pain, Postoperative; Preoperative Care; Prospective Studies; Pyrazoles; Sulfonamides; Sulfones	2005
COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003. The British journal of oral & maxillofacial surgery, 2006, Volume: 44, Issue:2 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ibuprofen; Injections, Intravenous; Isoxazoles; Lactones; Pain, Postoperative; Preanesthetic Medication; Prodrugs; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction	2006
More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis and rheumatism, 2006, Volume: 54, Issue:1 Topics: Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Heart Rate; Humans; Lactones; Male; Middle Aged; Pyrazoles; Sulfonamides; Sulfones	2006
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Current medical research and opinion, 2006, Volume: 22, Issue:1 Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Male; Middle Aged; Osteoarthritis; Placebos; Pyrazoles; Sulfonamides; Sulfones; Treatment Outcome	2006
Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. Current medical research and opinion, 2006, Volume: 22, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Double-Blind Method; Female; Humans; Lactones; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pyrazoles; Sulfonamides; Sulfones; Treatment Outcome	2006
Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? Journal of hypertension, 2006, Volume: 24, Issue:10 Topics: Aged; Aldosterone; Blood Pressure; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Female; Humans; Hypertension; Lactones; Middle Aged; Osteoarthritis; Prospective Studies; Pyrazoles; Sulfonamides; Sulfones	2006
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatology international, 2007, Volume: 27, Issue:5 Topics: Adenoma; Adenomatous Polyps; Angina, Unstable; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardial Infarction; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboembolism	2007
Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:12 Topics: Adult; Antigens, Neoplasm; Blood Platelets; Celecoxib; Cell Adhesion; Cyclic AMP; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Fibrinogen; Humans; Lactones; Leukocytes; Male; Naproxen; P-Selectin; Phospholipases A; Platelet Activation; Platelet Aggregation; Platelet Membrane Glycoprotein IIb; Prostaglandins; Pyrazoles; Reference Values; Sulfonamides; Sulfones; Thrombin; Thrombomodulin; Thromboxanes; Time Factors	2007
Efficiency and safety: comparison between preoperative analgesia and postoperative analgesia using non-steroidal anti-inflammatory drugs in patients receiving arthroscopic knee surgery in a multicenter, randomized, controlled study. Inflammopharmacology, 2021, Volume: 29, Issue:3 Topics: Adult; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Arthroscopy; Celecoxib; Female; Humans; Knee Joint; Lactones; Male; Middle Aged; Pain Management; Pain, Postoperative; Postoperative Care; Postoperative Nausea and Vomiting; Preoperative Care; Sulfones; Treatment Outcome	2021

Other Studies

348 other study(ies) available for celecoxib and rofecoxib

Article	Year
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. Journal of medicinal chemistry, 1999, Apr-08, Volume: 42, Issue:7 Topics: Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Biological Availability; Carrageenan; Cell Line; CHO Cells; Cricetinae; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cyclopentanes; Digestive System; Edema; Female; Fever; Humans; Hyperalgesia; Isoenzymes; Male; Membrane Proteins; Microsomes; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfones; Transfection	1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorganic & medicinal chemistry letters, 1999, Jul-05, Volume: 9, Issue:13 Topics: Administration, Oral; Animals; Biological Availability; CHO Cells; Cricetinae; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Humans; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Sulfones	1999
SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. Bioorganic & medicinal chemistry letters, 1999, Aug-02, Volume: 9, Issue:15 Topics: Administration, Oral; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Macaca mulatta; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Saimiri; Structure-Activity Relationship; U937 Cells	1999
A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 1999, Nov-15, Volume: 9, Issue:22 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; CHO Cells; Cricetinae; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Furans; Isoenzymes; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship	1999
Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors. Bioorganic & medicinal chemistry letters, 1999, Nov-15, Volume: 9, Issue:22 Topics: Animals; Biological Availability; CHO Cells; Cricetinae; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Furans; Humans; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats	1999
2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2001, Jan-22, Volume: 11, Issue:2 Topics: Animals; Arthritis, Experimental; Combinatorial Chemistry Techniques; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Edema; Foot Diseases; Furans; Inhibitory Concentration 50; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship	2001
Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere. Journal of medicinal chemistry, 2001, Aug-30, Volume: 44, Issue:18 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Azides; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Isoenzymes; Lactones; Membrane Proteins; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Structure-Activity Relationship; Sulfonamides; Sulfones	2001
Naphthalene derivatives: A new series of selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2001, Oct-22, Volume: 11, Issue:20 Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Inflammation; Isoenzymes; Naphthalenes; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship	2001
Structure-based design of cyclooxygenase-2 selectivity into ketoprofen. Bioorganic & medicinal chemistry letters, 2002, Feb-25, Volume: 12, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Humans; Inhibitory Concentration 50; Isoenzymes; Ketoprofen; Membrane Proteins; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Structure-Activity Relationship; Substrate Specificity	2002
Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. Journal of medicinal chemistry, 2002, Mar-28, Volume: 45, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Blood Platelets; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Humans; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Lactones; Membrane Proteins; Models, Chemical; Models, Molecular; Monocytes; Prostaglandin-Endoperoxide Synthases; Protein Binding; Protein Conformation; Pyrazoles; Sulfonamides; Sulfones	2002
4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1) Journal of medicinal chemistry, 2002, Mar-28, Volume: 45, Issue:7 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzenesulfonates; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fluorine; Humans; Inhibitory Concentration 50; Isoenzymes; Membrane Proteins; Models, Chemical; Oxazoles; Prostaglandin-Endoperoxide Synthases; Sulfonamides; Temperature	2002
Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2002, Oct-07, Volume: 12, Issue:19 Topics: Acetylation; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isomerism; Lactones; Membrane Proteins; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Sulfones	2002
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility. Bioorganic & medicinal chemistry letters, 2003, Mar-24, Volume: 13, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chemical Phenomena; Chemistry, Physical; CHO Cells; Cricetinae; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Fever; Furans; Humans; Isoenzymes; Membrane Proteins; Pain; Prostaglandin-Endoperoxide Synthases; Rats; Solubility; Structure-Activity Relationship; Substrate Specificity	2003
Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2003, May-19, Volume: 13, Issue:10 Topics: Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Furans; Heterocyclic Compounds, 4 or More Rings; Humans; Inhibitory Concentration 50; Isoenzymes; Membrane Proteins; Molecular Conformation; Prostaglandin-Endoperoxide Synthases; Structure-Activity Relationship	2003
6-Alkyl, alkoxy, or alkylthio-substituted 3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2003, Jul-07, Volume: 13, Issue:13 Topics: Alkanes; Binding Sites; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Heterocyclic Compounds; Hydrogen Bonding; Indicators and Reagents; Isoenzymes; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Prostaglandin-Endoperoxide Synthases; Pyrones; Structure-Activity Relationship; Sulfones	2003
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2003, Aug-05, Volume: 100, Issue:16 Topics: Adenosine Triphosphate; Alprostadil; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Transport; Cell Line; Cell Membrane; Diffusion; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Humans; Insecta; Multidrug Resistance-Associated Proteins; Prostaglandins; Prostaglandins A; Prostaglandins F; Ribosomal Proteins; RNA Interference; RNA, Small Interfering; Thromboxane B2; Time Factors	2003
Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles. Journal of medicinal chemistry, 2003, Jul-31, Volume: 46, Issue:16 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Imidazoles; Inflammation; Isoenzymes; Male; Membrane Proteins; Models, Molecular; Pain Measurement; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides	2003
Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation. Journal of medicinal chemistry, 2003, Sep-11, Volume: 46, Issue:19 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzenesulfonamides; Binding Sites; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Humans; Inhibitory Concentration 50; Isoenzymes; Male; Membrane Proteins; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sheep; Sodium; Spodoptera; Structure-Activity Relationship; Sulfonamides	2003
Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. Journal of medicinal chemistry, 2003, Nov-06, Volume: 46, Issue:23 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Edema; Isoenzymes; Membrane Proteins; Models, Molecular; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrans; Pyrones; Rats; Structure-Activity Relationship; Sulfones	2003
Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. Journal of medicinal chemistry, 2003, Dec-04, Volume: 46, Issue:25 Topics: Acute Disease; Administration, Oral; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cycloparaffins; Dioxolanes; Female; Humans; In Vitro Techniques; Inflammation; Isoenzymes; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship	2003
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. Journal of medicinal chemistry, 2004, Feb-12, Volume: 47, Issue:4 Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Furans; Humans; In Vitro Techniques; Isoenzymes; Macrophages, Peritoneal; Male; Membrane Proteins; Mice; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Structure-Activity Relationship	2004
Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & medicinal chemistry letters, 2004, Apr-19, Volume: 14, Issue:8 Topics: Alkenes; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Isoenzymes; Models, Molecular; Molecular Conformation; Prostaglandin-Endoperoxide Synthases; Stereoisomerism; Structure-Activity Relationship	2004
Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. Journal of medicinal chemistry, 2004, Apr-22, Volume: 47, Issue:9 Topics: Administration, Oral; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Gastritis; Humans; In Vitro Techniques; Isoenzymes; Male; Membrane Proteins; Nitrates; Nitric Oxide Donors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship	2004
Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. Journal of medicinal chemistry, 2004, Jul-29, Volume: 47, Issue:16 Topics: Analgesics; Animals; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Edema; Isoenzymes; Membrane Proteins; Models, Molecular; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrans; Pyrones; Rats; Stereoisomerism; Structure-Activity Relationship; Sulfones	2004
A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & medicinal chemistry letters, 2004, Oct-04, Volume: 14, Issue:19 Topics: Animals; Binding Sites; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Mice; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Structure-Activity Relationship	2004
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2004, Nov-01, Volume: 14, Issue:21 Topics: Administration, Oral; Animals; Arthritis, Experimental; Biological Availability; Brain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Freund's Adjuvant; Humans; Infusions, Intravenous; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridazines; Rats; Structure-Activity Relationship	2004
A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors. Journal of medicinal chemistry, 2004, Nov-18, Volume: 47, Issue:24 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzene Derivatives; Cyclooxygenase 2; Ethylenes; Isoenzymes; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Rats; Stereoisomerism; Structure-Activity Relationship	2004
3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & medicinal chemistry letters, 2004, Dec-20, Volume: 14, Issue:24 Topics: Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Evaluation, Preclinical; Humans; Isoenzymes; Membrane Proteins; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Structure-Activity Relationship	2004
New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. Journal of medicinal chemistry, 2004, Dec-02, Volume: 47, Issue:25 Topics: Animals; Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetinae; Cyclooxygenase 2; Drug Screening Assays, Antitumor; Humans; Isoenzymes; Lipoxygenase Inhibitors; Male; Membrane Proteins; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrazoles; Structure-Activity Relationship	2004
Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. Bioorganic & medicinal chemistry letters, 2005, Jan-17, Volume: 15, Issue:2 Topics: Animals; Binding Sites; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Ethylenes; Hydrocarbons, Aromatic; Inhibitory Concentration 50; Isoenzymes; Molecular Conformation; Prostaglandin-Endoperoxide Synthases; Sheep; Stereoisomerism; Structure-Activity Relationship	2005
1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors. Journal of medicinal chemistry, 2005, May-05, Volume: 48, Issue:9 Topics: Acetates; Animals; Binding Sites; Cell Line; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Esters; Membrane Proteins; Mice; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrroles	2005
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation. Journal of medicinal chemistry, 2005, Jun-02, Volume: 48, Issue:11 Topics: Administration, Oral; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Inflammation; Male; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Sprague-Dawley; Sulfones	2005
Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors. Journal of medicinal chemistry, 2005, Nov-03, Volume: 48, Issue:22 Topics: Binding Sites; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Ligands; Models, Molecular; Quantitative Structure-Activity Relationship; Thrombin	2005
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases. Journal of medicinal chemistry, 2006, Mar-09, Volume: 49, Issue:5 Topics: Administration, Oral; Alkynes; Analgesics; Animals; Arachidonate 15-Lipoxygenase; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Lipoxygenase Inhibitors; Mice; Models, Molecular; Pain Measurement; Rats; Structure-Activity Relationship	2006
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. Journal of medicinal chemistry, 2007, Apr-05, Volume: 50, Issue:7 Topics: Animals; Aorta; Cyclooxygenase 2 Inhibitors; Humans; Imidazoles; In Vitro Techniques; Models, Molecular; Muscle Contraction; Muscle, Smooth, Vascular; Nitric Oxide Donors; Rats; Structure-Activity Relationship; Sulfonamides; Vasodilator Agents	2007
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. European journal of medicinal chemistry, 2008, Volume: 43, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhibitors; Drug Design; Edema; Female; Foot; Formaldehyde; Inflammation; Male; Rats; Rats, Sprague-Dawley; Thiazoles	2008
Novel (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic ester prodrugs possessing a diazen-1-ium-1,2-diolate moiety: design, synthesis, cyclooxygenase inhibition, and nitric oxide release studies. Bioorganic & medicinal chemistry, 2007, Nov-01, Volume: 15, Issue:21 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Design; Humans; Imides; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Prostaglandin-Endoperoxide Synthases; Structure-Activity Relationship; Sulfones	2007
Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. Bioorganic & medicinal chemistry, 2008, Feb-15, Volume: 16, Issue:4 Topics: Alkynes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Humans; Inhibitory Concentration 50; Structure-Activity Relationship	2008
Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies. Bioorganic & medicinal chemistry, 2008, Mar-15, Volume: 16, Issue:6 Topics: Acrylates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Esters; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Rats; Serum; Structure-Activity Relationship	2008
2,3,5-Substituted tetrahydrofurans: COX-2 inhibitory activities of 5-hydroxymethyl-/carboxyl-2,3-diaryl-tetrahydro-furan-3-ols. European journal of medicinal chemistry, 2008, Volume: 43, Issue:12 Topics: Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Furans; Humans; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; Stereoisomerism	2008
Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorganic & medicinal chemistry, 2008, Apr-01, Volume: 16, Issue:7 Topics: Binding Sites; Blood Platelets; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Fluorine Compounds; Humans; Hydrogen Bonding; Indoles; Lipoxygenase Inhibitors; Magnetic Resonance Spectroscopy; Methylation; Models, Molecular; Molecular Structure; Pyrazoles; Stereoisomerism; Structure-Activity Relationship; Sulfur Compounds	2008
Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. Journal of medicinal chemistry, 2008, Aug-14, Volume: 51, Issue:15 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Computer Simulation; Cyclooxygenase 2 Inhibitors; Edema; Ether; Humans; Hydrophobic and Hydrophilic Interactions; Male; Mice; Models, Molecular; Molecular Structure; Pyrroles; Rats; Structure-Activity Relationship	2008
Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7 Topics: Animals; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 2 Inhibitors; Francisella tularensis; Humans; Lactones; Mice; Microbial Sensitivity Tests; Pyrazoles; Sulfonamides; Sulfones	2009
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15 Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Ethers; Humans; Inflammation; Inhibitory Concentration 50; Mice; Molecular Structure; Neurodegenerative Diseases; Pyrimidines; Rats; Sulfones	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Mono-, di-, and triaryl substituted tetrahydropyrans as cyclooxygenase-2 and tumor growth inhibitors. Synthesis and biological evaluation. Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9 Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Growth Inhibitors; Humans; Hydrocarbons, Aromatic; Protein Binding; Pyrans; Structure-Activity Relationship	2010
Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. Journal of medicinal chemistry, 2010, Sep-23, Volume: 53, Issue:18 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Screening Assays, Antitumor; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Models, Molecular; Rats; Stereoisomerism; Structure-Activity Relationship; Sulfones; Thermodynamics	2010
Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. Journal of medicinal chemistry, 2011, Apr-28, Volume: 54, Issue:8 Topics: Animals; Cyclooxygenase 2; Enzyme Inhibitors; Epoxide Hydrolases; Hydrogen Bonding; Magnetic Resonance Spectroscopy; Models, Molecular; Pyrazoles; Rats; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Urea	2011
Synthesis and biological evaluation of loxoprofen derivatives. Bioorganic & medicinal chemistry, 2011, Jun-01, Volume: 19, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cell Membrane Permeability; Computer Simulation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Gastric Mucosa; Phenylpropionates; Rats	2011
A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: synthesis, biological evaluation and nitric oxide release studies. Bioorganic & medicinal chemistry letters, 2011, Jul-01, Volume: 21, Issue:13 Topics: 4-Butyrolactone; Animals; Cyclooxygenase 2 Inhibitors; Esters; Inhibitory Concentration 50; Mesenteric Arteries; Molecular Structure; Nitric Oxide Donors; Prodrugs; Rats; Sulfones; Triazenes	2011
Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold. Journal of medicinal chemistry, 2012, Mar-08, Volume: 55, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Screening Assays, Antitumor; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Sheep; Stereoisomerism; Structure-Activity Relationship; Sulindac	2012
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker. Bioorganic & medicinal chemistry letters, 2013, Jan-01, Volume: 23, Issue:1 Topics: Acridines; Acridones; Biomarkers, Tumor; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fluorescent Dyes; Humans; Ibuprofen; Microscopy, Confocal; Protein Binding; Pyrazoles; Rhodamines; Structure-Activity Relationship; Sulfonamides	2013
Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones. European journal of medicinal chemistry, 2013, Volume: 65 Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Furans; Humans; Male; Molecular Structure; Prostatic Neoplasms; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured	2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity. Bioorganic & medicinal chemistry, 2014, Apr-15, Volume: 22, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Lactones; Lipid Bilayers; Liposomes; Protein Binding; Pyrazoles; Spectrometry, Fluorescence; Structure-Activity Relationship; Sulfonamides; Sulfones	2014
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach. European journal of medicinal chemistry, 2017, Oct-20, Volume: 139 Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxyprostaglandin Dehydrogenases; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured	2017
Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities. European journal of medicinal chemistry, 2019, Nov-15, Volume: 182 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Edema; Heterocyclic Compounds; Humans; Male; Molecular Docking Simulation; Molecular Structure; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship	2019
COX-2 inhibitors. Lancet (London, England), 1999, Jan-23, Volume: 353, Issue:9149 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	1999
Decisions loom on selective COX-2 inhibitors. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Jan-15, Volume: 56, Issue:2 Topics: Arthralgia; Arthritis; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	1999
Early trials probe COX-2 inhibitors' cancer-fighting potential. Journal of the National Cancer Institute, 1999, Jul-21, Volume: 91, Issue:14 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Colonic Neoplasms; Cyclooxygenase Inhibitors; Humans; Lactones; Neoplasms; Pyrazoles; Skin Neoplasms; Sulfonamides; Sulfones; Urinary Bladder Neoplasms	1999
[A new NSAID selective COX-2 inhibitor]. Revista espanola de enfermedades digestivas, 1999, Volume: 91, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	1999
[Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs]. Nederlands tijdschrift voor geneeskunde, 1999, Nov-13, Volume: 143, Issue:46 Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Lactones; Meloxicam; Nabumetone; Pyrazoles; Stomach Diseases; Sulfonamides; Sulfones; Thiazines; Thiazoles	1999
New versus old drugs for arthritis. Health news (Waltham, Mass.), 1999, Nov-20, Volume: 5, Issue:14 Topics: Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	1999
COX-2 inhibitors. Magic bullets or merely mortal? Harvard health letter, 2000, Volume: 25, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2000
COX-2-specific inhibition: implications for clinical practice. The Journal of the American Osteopathic Association, 1999, Volume: 99, Issue:11 Suppl Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Peroxidases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	1999
COX-2 inhibitors: better than ibuprofen for dental pain? Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995), 1999, Volume: 20, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Ibuprofen; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Toothache	1999
[Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?]. MMW Fortschritte der Medizin, 2000, Mar-16, Volume: 142, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Stomach Ulcer; Sulfonamides; Sulfones	2000
Patent prompts Rochester to sue for slice of drug profits. Science (New York, N.Y.), 2000, Apr-21, Volume: 288, Issue:5465 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cloning, Molecular; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Industry; Humans; Isoenzymes; Lactones; Membrane Proteins; New York; Patents as Topic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States; Universities	2000
The cox-2 inhibitors. Journal of the Massachusetts Dental Society, 1999,Fall, Volume: 48, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	1999
[Gastrointestinal damage induced by celecoxib and rofecoxib in rats]. Acta gastroenterologica Latinoamericana, 2000, Volume: 30, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Female; Gastric Mucosa; Intestine, Small; Lactones; Male; Peptic Ulcer Perforation; Pyrazoles; Rats; Rats, Wistar; Stomach Ulcer; Sulfonamides; Sulfones	2000
Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. Southern medical journal, 2000, Volume: 93, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis; Atrial Fibrillation; Bicarbonates; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Gastric Mucosa; Gastrointestinal Hemorrhage; Hip Joint; Humans; Hypoprothrombinemias; Incidence; Intestinal Mucosa; Isoenzymes; Lactones; Male; Membrane Proteins; Mucus; Peroxidases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Warfarin	2000
Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis. Biochemical and biophysical research communications, 2000, Nov-02, Volume: 277, Issue:3 Topics: Animals; Celecoxib; Cyanobacteria; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Insect Proteins; Isoenzymes; Lactones; Membrane Proteins; Microsomes; Phycocyanin; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sheep; Sulfonamides; Sulfones	2000
COX-2 inhibitors. The Medical journal of Australia, 2000, Oct-16, Volume: 173, Issue:8 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Kidney; Lactones; Membrane Proteins; Osteoarthritis; Peroxidases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2000
[Rheumatism therapy, from the economic viewpoint. COX-2 inhibitor as cost saving drug]. MMW Fortschritte der Medizin, 2000, Nov-02, Volume: 142, Issue:44 Topics: Arthritis, Rheumatoid; Celecoxib; Cost Savings; Cyclooxygenase Inhibitors; Drug Costs; Germany; Lactones; Pyrazoles; Sulfonamides; Sulfones	2000
The new COX-2 inhibitors. Celecoxib and rofecoxib. Indian journal of medical sciences, 2000, Volume: 54, Issue:7 Topics: Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interactions; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; United States	2000
FDA refuses companies' request to drop ulcer warning. BMJ (Clinical research ed.), 2001, Feb-17, Volume: 322, Issue:7283 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Labeling; Enzyme Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Stomach Ulcer; Sulfonamides; Sulfones	2001
Selective COX-2 inhibitors. The American journal of nursing, 2001, Volume: 101, Issue:4 Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Lactones; Osteoarthritis; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2001
Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Digestive diseases and sciences, 2001, Volume: 46, Issue:4 Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Female; Lactones; Male; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Sulfones	2001
EULAR recommendations for the management of knee osteoarthritis. Annals of the rheumatic diseases, 2001, Volume: 60, Issue:5 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis, Knee; Practice Guidelines as Topic; Pyrazoles; Sulfonamides; Sulfones	2001
Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. Neuropharmacology, 2001, Volume: 40, Issue:7 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Hyperalgesia; Isoenzymes; Lactones; Male; Membrane Proteins; Mice; Organic Chemicals; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Sulfones	2001
Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Advances in enzyme regulation, 2001, Volume: 41 Topics: Apoptosis; Calcium; Celecoxib; Cell Cycle; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Models, Chemical; Nitrobenzenes; Phosphatidylinositol 3-Kinases; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Signal Transduction; Sulfonamides; Sulfones; Thiophenes; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2001
Celecoxib- and rofecoxib-induced delirium. The Journal of neuropsychiatry and clinical neurosciences, 2001,Spring, Volume: 13, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Delirium; Female; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2001
Celecoxib-- the debate ranges on. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2001, Volume: 91, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Insurance Coverage; Lactones; Practice Guidelines as Topic; Pyrazoles; Rheumatic Diseases; Safety; Sulfonamides; Sulfones	2001
A new class of COX-2 inhibitors offer an alternative to NSAIDS in pain management after spinal surgery. Spine, 2001, Jul-01, Volume: 26, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Lumbar Vertebrae; Membrane Proteins; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Spinal Fusion; Sulfonamides; Sulfones	2001
[Safety of specific cyclo-oxygenase 2 inhibitors]. Nederlands tijdschrift voor geneeskunde, 2001, Jul-28, Volume: 145, Issue:30 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Gastritis; Humans; Lactones; Meloxicam; Netherlands; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles	2001
Pain relief at a price. A blow to the heart? U.S. news & world report, 2001, Sep-03, Volume: 131, Issue:8 Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Pain; Pyrazoles; Risk; Sulfonamides; Sulfones	2001
Arthritis: what it is, why you get it and how to stop the pain. Newsweek, 2001, Sep-03, Volume: 138, Issue:10 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain; Pyrazoles; Sulfonamides; Sulfones; United States	2001
How safe are your prescription pills? Time, 2001, Sep-03, Volume: 158, Issue:9 Topics: Celecoxib; Consumer Product Safety; Cyclooxygenase Inhibitors; Drug Prescriptions; Humans; Lactones; Meta-Analysis as Topic; Pyrazoles; Sulfonamides; Sulfones; United States	2001
[New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)]. MMW Fortschritte der Medizin, 2001, Sep-06, Volume: 143, Issue:35-36 Topics: Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Stomach Ulcer; Sulfonamides; Sulfones	2001
A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clinical therapeutics, 2001, Volume: 23, Issue:9 Topics: Acute Kidney Injury; Angiotensin Amide; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Databases as Topic; Drug Interactions; Heart Failure; Humans; Isoenzymes; Lactones; Membrane Proteins; Nephritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; World Health Organization	2001
Nonsteroidal anti-inflammatory drugs for perioperative pain control. Medicine and health, Rhode Island, 2001, Volume: 84, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Etodolac; Humans; Ibuprofen; Indomethacin; Ketorolac; Lactones; Nabumetone; Naproxen; Pain, Postoperative; Piroxicam; Pyrazoles; Sulfonamides; Sulfones; Time Factors	2001
Is concern about cardiovascular events with the new coxib class of drugs justified? Medscape women's health, 2001, Volume: 6, Issue:5 Topics: Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Drug Evaluation; Humans; Lactones; Myocardial Infarction; Pyrazoles; Stroke; Sulfonamides; Sulfones	2001
Cardiovascular safety of COX-2 inhibitors. The Medical letter on drugs and therapeutics, 2001, Nov-12, Volume: 43, Issue:1118 Topics: Cardiovascular Physiological Phenomena; Celecoxib; Consumer Product Safety; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Thrombosis	2001
Urticaria and angioedema from cyclooxygenase-2 inhibitors. The Journal of rheumatology, 2001, Volume: 28, Issue:11 Topics: Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Urticaria	2001
[Renal tolerance of selective inhibitors of cyclooxygenase type 2]. Presse medicale (Paris, France : 1983), 2001, Oct-20, Volume: 30, Issue:30 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Kidney; Kidney Diseases; Lactones; Naproxen; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rats; Risk Factors; Sulfonamides; Sulfones; Water-Electrolyte Imbalance	2001
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proceedings of the National Academy of Sciences of the United States of America, 2001, Dec-04, Volume: 98, Issue:25 Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones	2001
Cardiovascular events and COX-2 inhibitors. JAMA, 2001, Dec-12, Volume: 286, Issue:22 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Hypertension; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2001
[Thinking about the specific cyclooxygenase-2 inhibitors since its recommendation]. Zhonghua nei ke za zhi, 2001, Volume: 40, Issue:9 Topics: Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2001
[Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"]. MMW Fortschritte der Medizin, 2001, Nov-15, Volume: 143, Issue:46 Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Morphine; Pain, Postoperative; Pyrazoles; Risk Factors; Spinal Fusion; Sulfonamides; Sulfones; Time Factors	2001
[Side effects cause enormous costs. Expensive arthritis therapy]. MMW Fortschritte der Medizin, 2001, Nov-15, Volume: 143, Issue:46 Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Drug Costs; Gastrointestinal Diseases; Humans; Ibuprofen; Lactones; Nabumetone; Patient Satisfaction; Pyrazoles; Sulfonamides; Sulfones	2001
The coxibs, selective inhibitors of cyclooxygenase-2. The New England journal of medicine, 2001, Dec-06, Volume: 345, Issue:23 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Humans; International Normalized Ratio; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Warfarin	2001
GI events leading to death in association with celecoxib and rofecoxib. The American journal of gastroenterology, 2001, Volume: 96, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Middle Aged; Pyrazoles; Sulfonamides; Sulfones	2001
Celecoxib and rofecoxib. Journal of the American Dental Association (1939), 2001, Volume: 132, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Hemorrhage; Humans; Lactones; Middle Aged; Peptic Ulcer; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2001
[Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine]. Zeitschrift fur Rheumatologie, 2001, Volume: 60, Issue:6 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Evidence-Based Medicine; Germany; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Treatment Outcome	2001
[Improper use of selective COX-2 inhibitor NSAIDs]. Atencion primaria, 2002, Feb-15, Volume: 29, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Humans; Isoenzymes; Lactones; Membrane Proteins; Middle Aged; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2002
[Safety of celecoxib and rofecoxib: a critical overview]. Medicina clinica, 2002, Feb-23, Volume: 118, Issue:6 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2002
Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database. Current medical research and opinion, 2001, Volume: 17, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Celecoxib; Confidence Intervals; Cyclooxygenase Inhibitors; Drug Interactions; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; World Health Organization	2001
Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach. The American journal of cardiology, 2002, Mar-21, Volume: 89, Issue:6A Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular System; Celecoxib; Cyclooxygenase Inhibitors; Dysmenorrhea; Female; Humans; Isoxazoles; Lactones; Male; Pyrazoles; Sulfonamides; Sulfones	2002
Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer letters, 2002, Jun-06, Volume: 180, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Caspase 3; Caspases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Neuroectodermal Tumors, Primitive; Prostaglandin-Endoperoxide Synthases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazoles; Sulfonamides; Sulfones; Time Factors; Tumor Cells, Cultured	2002
COX-2 inhibition and thrombotic tendency. The Medical journal of Australia, 2002, Jan-21, Volume: 176, Issue:2 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pyrazoles; Sulfonamides; Sulfones; Venous Thrombosis	2002
Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. JAMA, 2002, Apr-10, Volume: 287, Issue:14 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Pyrazoles; Sulfonamides; Sulfones	2002
Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. JAMA, 2002, Apr-10, Volume: 287, Issue:14 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Pyrazoles; Sulfonamides; Sulfones	2002
[First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs]. Medicina clinica, 2002, Mar-30, Volume: 118, Issue:11 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Spain; Sulfonamides; Sulfones	2002
A comparison of the renal and cardiovascular safety of celecoxib and rofecoxib. Clinical therapeutics, 2002, Volume: 24, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Databases, Factual; Isoenzymes; Lactones; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; World Health Organization	2002
Characterization, quantification, and bioactivities of anthocyanins in Cornus species. Journal of agricultural and food chemistry, 2002, Apr-24, Volume: 50, Issue:9 Topics: Anthocyanins; Antioxidants; Celecoxib; Chromatography, High Pressure Liquid; Cornus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fruit; Ibuprofen; Isoenzymes; Lactones; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2002
Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. Journal of the National Cancer Institute, 2002, Apr-17, Volume: 94, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Doxycycline; Enzyme-Linked Immunosorbent Assay; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Isoenzymes; Lactones; Male; Membrane Proteins; Models, Chemical; Oligonucleotides, Antisense; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Time Factors; Tumor Cells, Cultured	2002
Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. Journal of the American Society of Nephrology : JASN, 2002, Volume: 13, Issue:5 Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Glomerular Mesangium; Glomerulonephritis, Membranoproliferative; Hemodynamics; Immunoenzyme Techniques; Lactones; Microscopy, Electron; Pyrazoles; Rats; Statistics, Nonparametric; Sulfonamides; Sulfones	2002
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. The American journal of gastroenterology, 2002, Volume: 97, Issue:4 Topics: Adult; Aged; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; Female; Humans; Intestines; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Pouchitis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Severity of Illness Index; Sulfonamides; Sulfones	2002
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr The Journal of rheumatology, 2002, Volume: 29, Issue:5 Topics: Aged; Arthritis, Rheumatoid; Bias; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Gastrointestinal Diseases; Health Services; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Severity of Illness Index; Sulfonamides; Sulfones	2002
Selective COX-2 inhibition. Bulletin on the rheumatic diseases, 1999, Volume: 48, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Pyrazoles; Sulfonamides; Sulfones	1999
Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2002, Volume: 9, Issue:3 Topics: Aedes; Amides; Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Echinacea; Ibuprofen; Isoenzymes; Lactones; Lethal Dose 50; Naproxen; Phytotherapy; Plant Extracts; Plant Roots; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2002
Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. Clinical therapeutics, 2002, Volume: 24, Issue:6 Topics: Celecoxib; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Diuretics; Edema; Humans; Hypertension; Lactones; Medicine; Osteoarthritis; Practice Patterns, Physicians'; Pyrazoles; Specialization; Sulfonamides; Sulfones; Surveys and Questionnaires	2002
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Jun-25, Volume: 166, Issue:13 Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardial Infarction; Osteoarthritis; Pyrazoles; Randomized Controlled Trials as Topic; Stomach Ulcer; Sulfonamides; Sulfones	2002
Seminal pharmaceutical trials: maintaining masking in analysis. Lancet (London, England), 2002, Jul-13, Volume: 360, Issue:9327 Topics: Celecoxib; Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Pyrazoles; Randomized Controlled Trials as Topic; Reproducibility of Results; Statistics as Topic; Sulfonamides; Sulfones	2002
Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs. BMJ (Clinical research ed.), 2002, Jul-20, Volume: 325, Issue:7356 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2002
Are selective COX 2 inhibitors superior to traditional NSAIDs? Little is known about COX 2 inhibitors. BMJ (Clinical research ed.), 2002, Jul-20, Volume: 325, Issue:7356 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Cell Division; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Tumor Cells, Cultured	2002
Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis. BMJ (Clinical research ed.), 2002, Jul-20, Volume: 325, Issue:7356 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2002
Hemicrania continua responds to cyclooxygenase-2 inhibitors. Headache, 2002, Volume: 42, Issue:6 Topics: Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Indomethacin; Lactones; Male; Migraine Disorders; Pyrazoles; Recurrence; Sulfonamides; Sulfones	2002
COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs. Health news (Waltham, Mass.), 2002, Volume: 8, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Labeling; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Stomach Ulcer; Sulfonamides; Sulfones	2002
Efficacy and safety of COX 2 inhibitors. BMJ (Clinical research ed.), 2002, Sep-21, Volume: 325, Issue:7365 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Assessment; Risk Factors; Sulfonamides; Sulfones	2002
Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ (Clinical research ed.), 2002, Sep-21, Volume: 325, Issue:7365 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2; Diclofenac; Drug Combinations; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hospitalization; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Misoprostol; Multivariate Analysis; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2002
[Analgesic in osteoporosis. Why so conservative with dosage?]. MMW Fortschritte der Medizin, 2002, Sep-05, Volume: 144, Issue:35-36 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Humans; Ibuprofen; Lactones; Middle Aged; Osteoporosis; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2002
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (London, England), 2002, Oct-05, Volume: 360, Issue:9339 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coronary Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Ibuprofen; Isoenzymes; Lactones; Male; Medicaid; Membrane Proteins; Middle Aged; Naproxen; Product Surveillance, Postmarketing; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Regression Analysis; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones; Tennessee	2002
Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:2 Topics: Animals; Arthritis, Experimental; Capillary Permeability; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Gastric Mucosa; Immunohistochemistry; Indomethacin; Isoenzymes; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Stomach Ulcer; Sulfonamides; Sulfones	2002
COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs. The American journal of managed care, 2002, Volume: 8, Issue:10 Topics: Celecoxib; Cost Control; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Utilization Review; Health Services Research; Humans; Isoenzymes; Lactones; Managed Care Programs; Membrane Proteins; Practice Patterns, Physicians'; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Sulfonamides; Sulfones; United States; United States Department of Veterans Affairs	2002
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology, 2002, Volume: 123, Issue:5 Topics: Animals; Aspirin; Celecoxib; Cell Adhesion; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Resistance; Gastric Mucosa; Hydroxyeicosatetraenoic Acids; Isoenzymes; Lactones; Leukocytes; Lipoxins; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Stomach; Sulfonamides; Sulfones	2002
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. British journal of pharmacology, 2002, Volume: 137, Issue:6 Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Edema; Hindlimb; Hyperalgesia; Indomethacin; Inflammation; Isoenzymes; Lactones; Male; Pain Threshold; Piroxicam; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Sulfonamides; Sulfones	2002
HMO drug formulary access increases for COX-2s. Managed care (Langhorne, Pa.), 2002, Volume: 11, Issue:10 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Formularies as Topic; Health Maintenance Organizations; Humans; Insurance, Pharmaceutical Services; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States	2002
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. The American journal of managed care, 2002, Volume: 8, Issue:15 Suppl Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cross-Sectional Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Data Collection; Drug Interactions; Female; Humans; Hypertension; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; United States	2002
Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. The American journal of managed care, 2002, Volume: 8, Issue:15 Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Female; Health Care Costs; Heart Failure; Humans; Hypertension; Insurance Claim Review; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones; United States	2002
[Financial interests characterize published reports on coxiber. Whom can we rely on?]. Lakartidningen, 2002, Oct-03, Volume: 99, Issue:40 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Celecoxib; Conflict of Interest; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Periodicals as Topic; Publication Bias; Publishing; Pyrazoles; Randomized Controlled Trials as Topic; Research Support as Topic; Sulfonamides; Sulfones	2002
[The CLASS study and its scientific statement. Ethical publishing rules neglected]. Lakartidningen, 2002, Oct-03, Volume: 99, Issue:40 Topics: Antirheumatic Agents; Celecoxib; Conflict of Interest; Cyclooxygenase Inhibitors; Humans; Lactones; Periodicals as Topic; Publication Bias; Publishing; Pyrazoles; Randomized Controlled Trials as Topic; Research Support as Topic; Sulfonamides; Sulfones	2002
Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Nov-12, Volume: 167, Issue:10 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Costs; Female; Humans; Lactones; Male; Osteoarthritis; Pyrazoles; Sulfonamides; Sulfones	2002
A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. British journal of clinical pharmacology, 2002, Volume: 54, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Prescriptions; Family Practice; Humans; Isoenzymes; Lactones; Medical Audit; Membrane Proteins; Middle Aged; Osteoarthritis; Practice Patterns, Physicians'; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Queensland; Risk Factors; Rural Health; Sulfonamides; Sulfones	2002
Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. Journal of the National Cancer Institute, 2002, Dec-04, Volume: 94, Issue:23 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Celecoxib; Cyclooxygenase 2; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Mitogen-Activated Protein Kinase 1; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazoles; Signal Transduction; Structure-Activity Relationship; Sulfonamides; Sulfones; Tumor Cells, Cultured	2002
COX-2 inhibitors: new drugs for the management of pain and inflammation. Dentistry today, 2001, Volume: 20, Issue:2 Topics: Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Inflammation Mediators; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Peroxidases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Safety; Sulfonamides; Sulfones	2001
Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2002, Volume: 51, Issue:12 Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dexamethasone; Dinoprostone; Edema; Indomethacin; Inflammation; Interleukin-1; Isoenzymes; Lactones; Male; Nitric Oxide; Peroxidase; Pleurisy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Sulfones; Thromboxane B2; Tumor Necrosis Factor-alpha	2002
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Archives of internal medicine, 2003, Feb-24, Volume: 163, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Male; Myocardial Infarction; Naproxen; Ontario; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones	2003
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clinical therapeutics, 2003, Volume: 25, Issue:1 Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Hypertension; Isoenzymes; Kidney Diseases; Lactones; Male; Managed Care Programs; Membrane Proteins; Middle Aged; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones; United States	2003
[Rapid, strong and long-term effectiveness. Coxib also effective in toothache]. MMW Fortschritte der Medizin, 2003, Jan-16, Volume: 145, Issue:1-2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Ibuprofen; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Tooth Extraction; Toothache; Treatment Outcome	2003
Anti-inflammatory drugs may put on the pressure. Harvard heart letter : from Harvard Medical School, 2003, Volume: 13, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase Inhibitors; Humans; Hypertension; Lactones; Pyrazoles; Sulfonamides; Sulfones	2003
Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site? Journal of medicinal chemistry, 2003, Apr-10, Volume: 46, Issue:8 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Lactones; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Protein Binding; Pyrazoles; Solvents; Sulfonamides; Sulfones; Thermodynamics	2003
[Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered]. MMW Fortschritte der Medizin, 2003, Mar-06, Volume: 145, Issue:10 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Gastrointestinal Hemorrhage; Humans; Lactones; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Time Factors	2003
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart]. MMW Fortschritte der Medizin, 2003, Mar-13, Volume: 145, Issue:11 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Osteoarthritis; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Sulfonamides; Sulfones	2003
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis. The American journal of cardiology, 2003, May-15, Volume: 91, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cyclooxygenase Inhibitors; Edema; Heart Failure; Humans; Hypertension; Lactones; Osteoarthritis; Pyrazoles; Sulfonamides; Sulfones	2003
A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. Clinical therapeutics, 2003, Volume: 25, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Costs and Cost Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Data Collection; Double-Blind Method; Edema; Female; Humans; Hypertension; Isoenzymes; Lactones; Male; Medicare; Membrane Proteins; Osteoarthritis; Practice Patterns, Physicians'; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2003
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis. Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Decision Support Techniques; Humans; Isoenzymes; Lactones; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quality-Adjusted Life Years; Recurrence; Sensitivity and Specificity; Stomach Ulcer; Sulfonamides; Sulfones	2003
A side effect of COX-2 inhibitors. Harvard health letter, 2003, Volume: 28, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2003
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and rheumatism, 2003, Jun-15, Volume: 49, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Canada; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Drug Costs; Female; Gastrointestinal Diseases; Humans; Lactones; Male; Markov Chains; Middle Aged; Osteoarthritis; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones	2003
Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity. Acta dermato-venereologica, 2003, Volume: 83, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2003
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology, 2003, Volume: 125, Issue:2 Topics: Adenoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Neoplasm Recurrence, Local; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2003
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflammatory bowel diseases, 2003, Volume: 9, Issue:4 Topics: Animals; Celecoxib; Colitis; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Disease Models, Animal; Immunohistochemistry; Interleukin-10; Lactones; Mice; Mice, Knockout; Precancerous Conditions; Pyrazoles; Sulfonamides; Sulfones	2003
Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut, 2003, Volume: 52, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Bias; Celecoxib; Cohort Studies; Databases, Factual; Family Practice; Female; Gastrointestinal Hemorrhage; Humans; Lactones; Male; Meloxicam; Middle Aged; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Thiazines; Thiazoles	2003
Adverse Drug Events Involving COX-2 Inhibitors. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:9 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Drug Interactions; Gastrointestinal Diseases; Heart Diseases; Hospitalization; Humans; International Normalized Ratio; Isoenzymes; Kidney Diseases; Lactones; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2003
Effects of rofecoxib, celecoxib, and parecoxib on anti-IgE-induced histamine release from human skin mast cells and basophils. Allergy, 2003, Volume: 58, Issue:10 Topics: Antibodies, Anti-Idiotypic; Basophils; Celecoxib; Cyclooxygenase Inhibitors; Histamine Release; Humans; Isoxazoles; Lactones; Mast Cells; Pyrazoles; Skin; Sulfonamides; Sulfones	2003
Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. The Medical journal of Australia, 2003, Oct-20, Volume: 179, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Australia; Celecoxib; Child; Cohort Studies; Cyclooxygenase Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Family Practice; Female; Humans; Lactones; Male; Middle Aged; Pyrazoles; Sulfonamides; Sulfones	2003
Role of cyclooxygenase enzymes in a murine model of experimental cholera. Infection and immunity, 2003, Volume: 71, Issue:11 Topics: Aldehydes; Animals; Celecoxib; Cholera; Cholera Toxin; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; Female; Glutathione; Isoenzymes; Lactones; Leukotriene B4; Malondialdehyde; Membrane Proteins; Mice; Mice, Inbred C57BL; Oxidative Stress; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Tumor Necrosis Factor-alpha	2003
Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology (Oxford, England), 2003, Volume: 42 Suppl 3 Topics: Adolescent; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Quebec; Retrospective Studies; Sulfonamides; Sulfones; Survival Rate; Time Factors	2003
Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford, England), 2003, Volume: 42 Suppl 3 Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; Drug Utilization; Female; Humans; Lactones; Male; Middle Aged; Misoprostol; Netherlands; Peptic Ulcer; Prognosis; Pyrazoles; Referral and Consultation; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones	2003
Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation, 2003, Nov-11, Volume: 108, Issue:19 Topics: Acetylcholine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Endothelium, Vascular; Enzyme Inhibitors; F2-Isoprostanes; Hypertension; Interleukin-1; Isoenzymes; Lactones; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred Dahl; Safety; Sodium Chloride, Dietary; Sulfonamides; Sulfones; Vasodilation	2003
Persistence with COX-2 inhibitors in managed care: an analysis of claims data. Managed care interface, 2003, Volume: 16, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Utilization Review; Female; Health Care Costs; Humans; Ibuprofen; Insurance Claim Review; Isoenzymes; Lactones; Male; Managed Care Programs; Membrane Proteins; Middle Aged; Naproxen; Patient Compliance; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Regression Analysis; Sulfonamides; Sulfones; United States	2003
Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. Pharmacotherapy, 2003, Volume: 23, Issue:11 Topics: Aged; Aged, 80 and over; Ambulatory Care; Antihypertensive Agents; Blood Pressure; Celecoxib; Chi-Square Distribution; Cohort Studies; Female; Humans; Hypertension; Lactones; Linear Models; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Sulfonamides; Sulfones	2003
Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech, 2003, Volume: 4, Issue:3 Topics: Celecoxib; Chemistry, Pharmaceutical; Cyclooxygenase 2; Enzyme Inhibitors; Hydrogen-Ion Concentration; Isoenzymes; Lactones; Meloxicam; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Solubility; Solvents; Sulfonamides; Sulfones; Thiazines; Thiazoles	2003
Why don't we initiate more large simple randomized controlled trials? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003, Nov-25, Volume: 169, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Canada; Celecoxib; Consumer Product Safety; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2003
Studies on the anti-inflammatory effect of fluoxetine in the rat. Pharmacological research, 2004, Volume: 49, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Carrageenan; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Edema; Fluoxetine; Foot; Imipramine; Indomethacin; Inflammation; Lactones; Melatonin; Pyrazoles; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sulfonamides; Sulfones; Time Factors; Trazodone	2004
Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:6 Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Eruptions; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Urticaria	2003
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer biology & therapy, 2004, Volume: 3, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Glioblastoma; Humans; Indomethacin; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Sulindac	2004
Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-01, Volume: 10, Issue:1 Pt 1 Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Caspases; Celecoxib; Cell Cycle; Cell Line, Transformed; Cyclooxygenase Inhibitors; Enterocytes; Enzyme-Linked Immunosorbent Assay; Genes, ras; In Vitro Techniques; Lactones; Pyrazoles; Rats; Sulfonamides; Sulfones	2004
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. Journal of medicinal chemistry, 2004, Jan-29, Volume: 47, Issue:3 Topics: Animals; Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Intraocular Pressure; Isoenzymes; Isoxazoles; Kinetics; Lactones; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Structure-Activity Relationship; Sulfonamides; Sulfones	2004
Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. The Medical journal of Australia, 2004, Feb-02, Volume: 180, Issue:3 Topics: Australia; Celecoxib; Cyclooxygenase Inhibitors; Family Practice; Humans; Lactones; Practice Patterns, Physicians'; Pyrazoles; Sulfonamides; Sulfones	2004
An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clinical therapeutics, 2003, Volume: 25, Issue:12 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Databases, Factual; Drug Utilization Review; Female; Humans; Lactones; Male; Osteoarthritis; Practice Patterns, Physicians'; Pyrazoles; Retrospective Studies; Sulfonamides; Sulfones	2003
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. The Journal of rheumatology, 2004, Volume: 31, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Fibromyalgia; Follow-Up Studies; Humans; Ibuprofen; Isoenzymes; Lactones; Longitudinal Studies; Male; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Surveys and Questionnaires	2004
Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. The Medical journal of Australia, 2004, Mar-15, Volume: 180, Issue:6 Topics: Australia; Celecoxib; Cyclooxygenase Inhibitors; Drug Utilization; Family Practice; Humans; Lactones; Practice Patterns, Physicians'; Pyrazoles; Sulfonamides; Sulfones	2004
[Homeopathy suppresses COX- and LOX activity. Soft therapy for arthrosis ills]. MMW Fortschritte der Medizin, 2004, Jan-29, Volume: 146, Issue:5 Topics: Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Formularies, Homeopathic as Topic; Homeopathy; Humans; Lactones; Lipoxygenase Inhibitors; Multicenter Studies as Topic; Osteoarthritis, Knee; Placebos; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Time Factors	2004
[Clinical pharmacology of selective inhibitors of cyclooxygenase-2]. Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2003, Volume: 23, Issue:4 Suppl 74 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Inflammation; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Sulfones	2003
Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland. Pharmacoepidemiology and drug safety, 2004, Volume: 13, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Drug Prescriptions; Drug Utilization; Gastrointestinal Agents; Humans; Isoenzymes; Lactones; Linear Models; Membrane Proteins; Northern Ireland; Practice Patterns, Physicians'; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Proton Pumps; Pyrazoles; Sulfonamides; Sulfones; Time Factors	2004
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation, 2004, May-04, Volume: 109, Issue:17 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; Hospitalization; Humans; Isoenzymes; Lactones; Male; Medicare; Membrane Proteins; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Time Factors	2004
Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs & aging, 2004, Volume: 21, Issue:7 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Female; Hospitalization; Humans; Hypertension; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Nabumetone; Oxaprozin; Propionates; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2004
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiology and drug safety, 2004, Volume: 13, Issue:5 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Female; Gastrointestinal Diseases; Humans; Lactones; Male; Middle Aged; Osteoarthritis; Pharmacoepidemiology; Proportional Hazards Models; Pyrazoles; Sulfonamides; Sulfones; Time Factors	2004
Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-15, Volume: 10, Issue:10 Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; Cell Membrane; Cell Survival; Cytoplasm; Cytosol; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Flow Cytometry; Fluorescein-5-isothiocyanate; Granzymes; HSP70 Heat-Shock Proteins; Humans; Immunoblotting; Immunotherapy; Insulin; Kinetics; Lactones; Models, Chemical; Neoplasms; Pioglitazone; Pyrazoles; Serine Endopeptidases; Sulfonamides; Sulfones; Thiazolidinediones; Up-Regulation	2004
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. The Journal of rheumatology, 2004, Volume: 31, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Cyclooxygenase 2; Edema; Female; Humans; Hypertension; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Severity of Illness Index; Sulfonamides; Sulfones; Surveys and Questionnaires; Treatment Outcome	2004
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet (London, England), 2004, May-29, Volume: 363, Issue:9423 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; Female; Heart Failure; Hospitalization; Humans; Hypertension; Lactones; Male; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones	2004
Lipopolysaccharide-induced paw edema model for detection of cytokine modulating anti-inflammatory agents. International immunopharmacology, 2004, Volume: 4, Issue:7 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Edema; Female; Hindlimb; Interleukin-1; Interleukin-6; Lactones; Lipopolysaccharides; NF-kappa B; Peritoneal Cavity; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Sulfones; Tumor Necrosis Factor-alpha	2004
Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint bone spine, 2004, Volume: 71, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Utilization; Female; France; Gastrointestinal Tract; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Practice Patterns, Physicians'; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2004
Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochemical pharmacology, 2004, Jul-15, Volume: 68, Issue:2 Topics: Apoptosis; Celecoxib; Cell Cycle; Cell Cycle Proteins; Cell Division; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endothelium, Vascular; Epoprostenol; Gene Expression; Humans; Isoenzymes; Lactones; Membrane Proteins; Muscle, Smooth, Vascular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Thromboxanes	2004
Hypertension associated with therapies to treat arthritis and pain. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Interactions; Heart Diseases; Humans; Hypertension; Kidney Diseases; Lactones; Osteoarthritis; Pain; Pyrazoles; Sulfonamides; Sulfones	2004
Relationship between COX-2 specific inhibitors and hypertension. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:2 Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Hypertension; Lactones; Male; Multivariate Analysis; Osteoarthritis; Pyrazoles; Random Allocation; Retrospective Studies; Risk Assessment; Sex Distribution; Sulfonamides; Sulfones	2004
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. Bulletin du cancer, 2004, Volume: 91 Spec No Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Hypertension; Isoenzymes; Kidney; Lactones; Membrane Proteins; Myocardial Infarction; Neoplasm Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2004
Multiple comparisons with a control in families with both one-sided and two-sided hypotheses. Statistics in medicine, 2004, Oct-15, Volume: 23, Issue:19 Topics: Aged; Anti-Inflammatory Agents; Celecoxib; Clinical Trials as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Lactones; Naproxen; Pyrazoles; Research Design; Sodium; Sulfonamides; Sulfones	2004
Coxibs and cardiovascular disease. The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration	2004
Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:10 Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; Databases as Topic; Esophageal Neoplasms; Female; Humans; Incidence; Lactones; Logistic Models; Male; Pyrazoles; Quebec; Risk Factors; Sex Factors; Sulfonamides; Sulfones	2004
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Fundamental & clinical pharmacology, 2004, Volume: 18, Issue:5 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Flurbiprofen; Ibuprofen; Isoenzymes; Lactones; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Thrombosis	2004
Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. European journal of clinical pharmacology, 2004, Volume: 60, Issue:9 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Databases, Factual; Duodenitis; Esophagitis; Female; France; Gastritis; Gastrointestinal Diseases; Humans; Lactones; Male; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Sulfonamides; Sulfones; Ulcer; Upper Gastrointestinal Tract	2004
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis, 2004, Volume: 177, Issue:2 Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles	2004
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cohort Studies; Coronary Disease; Cost Savings; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Health Care Costs; Health Expenditures; Humans; Hypertension; Incidence; Lactones; Life Expectancy; Male; Markov Chains; Models, Cardiovascular; Osteoarthritis; Prevalence; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Sulfonamides; Sulfones; United States	2005
Vioxx withdrawal alarms cancer prevention researchers. Journal of the National Cancer Institute, 2004, Dec-01, Volume: 96, Issue:23 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Estrogen Receptor Modulators; Humans; Lactones; Neoplasms; Pyrazoles; Sulfonamides; Sulfones; Tamoxifen; United States; United States Food and Drug Administration	2004
Clinical trials. Nail-biting time for trials of COX-2 drugs. Science (New York, N.Y.), 2004, Dec-03, Volume: 306, Issue:5702 Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Intestinal Polyps; Lactones; Neoplasms; Patient Selection; Pyrazoles; Sulfonamides; Sulfones	2004
Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors. Journal of the American Academy of Dermatology, 2004, Volume: 51, Issue:6 Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Drug Eruptions; Female; Humans; Lactones; Male; Middle Aged; Pyrazoles; Sulfonamides; Sulfones; Vasculitis, Leukocytoclastic, Cutaneous	2004
Linking pharmacovigilance with pharmacogenetics. Drug safety, 2004, Volume: 27, Issue:15 Topics: Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP2C9; DNA; Genes, MDR; Genetic Predisposition to Disease; Genetic Testing; Genotype; Humans; Lactones; Mental Disorders; New Zealand; Pharmacogenetics; Pilot Projects; Polymorphism, Genetic; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; Vision Disorders	2004
Rofecoxib, Merck, and the FDA. The New England journal of medicine, 2004, Dec-30, Volume: 351, Issue:27 Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interactions; Gastrointestinal Diseases; History, 20th Century; History, 21st Century; Humans; Lactones; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2004
Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids. Biomedical chromatography : BMC, 2005, Volume: 19, Issue:5 Topics: Butanones; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Nabumetone; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Sulfones	2005
Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:2 Topics: Animals; Blood Pressure; Blood Vessels; C-Reactive Protein; CD8-Positive T-Lymphocytes; Celecoxib; Cell Count; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Hemodynamics; Hypertension; Immunohistochemistry; Kidney; Kidney Cortex; Kidney Glomerulus; Lactones; Monocytes; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred Dahl; RNA, Messenger; Sodium Chloride; Sulfonamides; Sulfones	2005
The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. European journal of pharmacology, 2005, Jan-10, Volume: 507, Issue:1-3 Topics: Acetic Acid; Animals; Celecoxib; Colitis; Cyclooxygenase Inhibitors; Lactones; Male; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Sulfones	2005
[Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall]. Klinische Monatsblatter fur Augenheilkunde, 2005, Volume: 222, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Colonic Polyps; Costs and Cost Analysis; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Germany; Humans; Lactones; Long-Term Care; Multicenter Studies as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Retinal Vein Occlusion; Risk; Secondary Prevention; Sulfonamides; Sulfones; United States; Vision Disorders	2005
Summaries for patients. Cyclooxygenase-2 inhibitors and heart attacks: varying effects? Annals of internal medicine, 2005, Feb-01, Volume: 142, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2005
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Annals of internal medicine, 2005, Feb-01, Volume: 142, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2005
COX-2 inhibitors: cancer prevention or cardiovascular risk? The Lancet. Oncology, 2005, Volume: 6, Issue:2 Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Membrane Proteins; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2005
COX-2 inhibitors--lessons in drug safety. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Publishing; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
COX-2 inhibitors--a lesson in unexpected problems. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2005
Vioxx may go back on sale after scraping past FDA panel. Nature, 2005, Feb-24, Volume: 433, Issue:7028 Topics: Celecoxib; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Science (New York, N.Y.), 2005, Feb-25, Volume: 307, Issue:5713 Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Stroke; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis research & therapy, 2005, Volume: 7, Issue:2 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Contraindications; Cyclooxygenase 2 Inhibitors; Databases, Factual; Drug Prescriptions; Drug Utilization; Female; Formularies as Topic; Gastritis; Gastrointestinal Hemorrhage; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Lactones; Logistic Models; Male; Medicine; Middle Aged; Multivariate Analysis; Prevalence; Pyrazoles; Quebec; Risk Factors; Sampling Studies; Sex Factors; Specialization; Sulfonamides; Sulfones	2005
Painful lessons. Nature structural & molecular biology, 2005, Volume: 12, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Design; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2005
Drug fiasco highlights need for more openness. British journal of community nursing, 2005, Volume: 10, Issue:1 Topics: Celecoxib; Contraindications; Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; United Kingdom	2005
The safety of the perioperative administration of cyclooxygenase-2 inhibitors for post-surgical pain. Acta anaesthesiologica Scandinavica, 2005, Volume: 49, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty; Blood Loss, Surgical; Celecoxib; Child; Cyclooxygenase Inhibitors; Humans; Lactones; Pain, Postoperative; Perioperative Care; Postoperative Complications; Pyrazoles; Sulfonamides; Sulfones; Tonsillectomy; Treatment Outcome	2005
Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole. The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:3 Topics: Adult; Anaphylaxis; Anti-Infective Agents; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Pyrazoles; Skin Tests; Sulfamethoxazole; Sulfonamides; Sulfones	2005
Factors associated with celecoxib and rofecoxib utilization. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:4 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Confidence Intervals; Databases, Factual; Drug Prescriptions; Female; Health Care Sector; Humans; Lactones; Logistic Models; Male; Middle Aged; Odds Ratio; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2005
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-01, Volume: 11, Issue:5 Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Male; Membrane Proteins; Mice; Mice, Nude; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrazoles; Sulfonamides; Sulfones; Transplantation, Heterologous; Tumor Cells, Cultured	2005
Cyclooxygenase-2 inhibitors and cardiovascular risk. The Canadian journal of cardiology, 2005, Volume: 21, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Canada; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Industry; Drug Labeling; Humans; Incidence; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Risk Factors; Sulfonamides; Sulfones	2005
Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors. European journal of clinical pharmacology, 2005, Volume: 61, Issue:1 Topics: Adult; Celecoxib; Cyclooxygenase Inhibitors; Databases, Factual; Female; Humans; Lactones; Male; Middle Aged; Pharmacoepidemiology; Practice Patterns, Physicians'; Pyrazoles; Queensland; Rural Population; Seasons; Sulfonamides; Sulfones; Surveys and Questionnaires; Urban Population	2005
[Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005, Volume: 25, Issue:1 Topics: Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Nephritis, Interstitial; Pyrazoles; Sulfonamides; Sulfones	2005
A tale of two coxibs. JAAPA : official journal of the American Academy of Physician Assistants, 2005, Volume: 18, Issue:3 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005, Apr-01, Volume: 62, Issue:7 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Drug Prescriptions; Drug Utilization; Female; Humans; Lactones; Male; Middle Aged; Nabumetone; Outpatients; Oxaprozin; Practice Patterns, Physicians'; Propionates; Pyrazoles; Sulfonamides; Sulfones	2005
COX-2 inhibitors and cardiovascular toxicity: a class effect? South Dakota journal of medicine, 2005, Volume: 58, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2005
Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation, 2005, Apr-05, Volume: 111, Issue:13 Topics: Aorta; Celecoxib; Cells, Cultured; Cyclooxygenase Inhibitors; Endothelium, Vascular; Humans; JNK Mitogen-Activated Protein Kinases; Lactones; Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazoles; Signal Transduction; Sulfonamides; Sulfones; Thromboplastin; Tumor Necrosis Factor-alpha	2005
Blood pressure in Native Americans switched from celecoxib to rofecoxib. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arizona; Blood Pressure; Celecoxib; Chemistry, Pharmaceutical; Cyclooxygenase Inhibitors; Female; Humans; Hypertension; Indians, North American; Lactones; Male; Medical Records Systems, Computerized; Middle Aged; Pyrazoles; Retrospective Studies; Sulfonamides; Sulfones	2005
Raising the safety bar--the FDA's coxib meeting. The New England journal of medicine, 2005, Mar-31, Volume: 352, Issue:13 Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Adoption of celecoxib and rofecoxib: a nationwide database study. Journal of clinical pharmacy and therapeutics, 2005, Volume: 30, Issue:2 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Child; Databases, Factual; Drug Utilization Review; Finland; Humans; Insurance, Pharmaceutical Services; Lactones; Medicine; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Pyrazoles; Retrospective Studies; Sex Factors; Specialization; Sulfonamides; Sulfones; Time Factors	2005
Does the dose make the poison? Science (New York, N.Y.), 2005, Apr-08, Volume: 308, Issue:5719 Topics: Celecoxib; Colonic Polyps; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones	2005
Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy? American journal of physiology. Regulatory, integrative and comparative physiology, 2005, Volume: 288, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Design; Humans; Intramolecular Oxidoreductases; Isoxazoles; Lactones; Microsomes; Prostaglandin-E Synthases; Pyrazoles; Sulfonamides; Sulfones	2005
Institutional review boards must conduct safety review. Human research report, 2005, Volume: 20, Issue:2 Topics: Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Cyclooxygenase Inhibitors; Ethics Committees, Research; Humans; Lactones; National Institutes of Health (U.S.); Pyrazoles; Research Subjects; Safety; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. Journal of the National Cancer Institute, 2005, Apr-20, Volume: 97, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Incidence; Isoxazoles; Lactones; Membrane Proteins; Meta-Analysis as Topic; Myocardial Infarction; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Reassessment of the benefit/risk-ratio of selective COX-2-inhibitors. Swiss medical weekly, 2005, Mar-19, Volume: 135, Issue:11-12 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2005
COX-2 inhibitors still eyed for cancer prevention. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005, May-01, Volume: 62, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Celecoxib; Colonic Neoplasms; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones	2005
Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. Drug safety, 2005, Volume: 28, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Female; Humans; Intracranial Thrombosis; Lactones; Male; Middle Aged; New Zealand; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; Surveys and Questionnaires	2005
A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts. The Journal of pharmacology and experimental therapeutics, 2005, Volume: 314, Issue:2 Topics: Apoptosis; Blotting, Western; Caspase Inhibitors; Caspases; Celecoxib; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclooxygenase Inhibitors; Dinoprostone; DNA Fragmentation; Enzyme Inhibitors; Fibroblasts; Genes, bcl-2; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Synovial Membrane	2005
High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2005, Volume: 52, Issue:5 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Female; Humans; Ketorolac; Lactones; Male; Middle Aged; Pain, Postoperative; Pyrazoles; Retrospective Studies; Spinal Fusion; Sulfonamides; Sulfones	2005
Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Current medical research and opinion, 2005, Volume: 21, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Pyrazoles; Quality-Adjusted Life Years; Risk Factors; Sulfonamides; Sulfones; United States; United States Department of Veterans Affairs	2005
Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Archives of internal medicine, 2005, May-09, Volume: 165, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase Inhibitors; Denmark; Female; Hospitalization; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2005
Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:10 Topics: Adenomatous Polyposis Coli Protein; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; beta Catenin; Cadherins; Caspases; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2; DNA; Flurbiprofen; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunohistochemistry; Lactones; Proteasome Endopeptidase Complex; Pyrazoles; Signal Transduction; Sulfonamides; Sulfones; TCF Transcription Factors	2005
Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ (Clinical research ed.), 2005, Jun-11, Volume: 330, Issue:7504 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; Female; Heart Failure; Humans; Lactones; Male; Prognosis; Pyrazoles; Recurrence; Risk Factors; Sulfonamides; Sulfones; Survival Analysis	2005
Tailoring arthritis therapy in the wake of the NSAID crisis. The New England journal of medicine, 2005, Jun-23, Volume: 352, Issue:25 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2005
Cardiovascular risk associated with celecoxib. The New England journal of medicine, 2005, Jun-23, Volume: 352, Issue:25 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Humans; Lactones; Pyrazoles; Risk; Sulfonamides; Sulfones	2005
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. Yale journal of health policy, law, and ethics, 2005,Summer, Volume: 5, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromans; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Humans; Hypoglycemic Agents; Isoxazoles; Lactones; Myocardial Infarction; Paternalism; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; Thiazolidinediones; Troglitazone; Truth Disclosure; United States; United States Food and Drug Administration; Vasodilator Agents	2005
A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. Drug safety, 2005, Volume: 28, Issue:9 Topics: Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones; Thromboembolism	2005
COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database. European journal of clinical pharmacology, 2005, Volume: 61, Issue:8 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; France; Humans; Hypertension; Lactones; Male; Middle Aged; Odds Ratio; Pyrazoles; Sulfonamides; Sulfones	2005
Concerns about COX-2 painkillers. They're easier on the stomach, potentially harder on your heart. Heart advisor, 2002, Volume: 5, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2002
The Vioxx debacle revisited. The American journal of medicine, 2005, Volume: 118, Issue:9 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pyrazoles; Sulfonamides; Sulfones	2005
Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography. Journal of chromatographic science, 2005, Volume: 43, Issue:7 Topics: Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Humans; Lactones; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Sulfones	2005
Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug safety, 2005, Volume: 28, Issue:10 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Isoxazoles; Lactones; Male; Middle Aged; Pyrazoles; Stevens-Johnson Syndrome; Sulfonamides; Sulfones	2005
A real time quantitative PCR analysis and correlation of COX-1 and COX-2 enzymes in inflamed dental pulps following administration of three different NSAIDs. Journal of endodontics, 2005, Volume: 31, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dental Pulp Exposure; Ibuprofen; Lactones; Male; Pulpitis; Pyrazoles; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Sulfones	2005
[Cyclooxygenase-2 inhibitors and the ethics of research]. Medicina, 2005, Volume: 65, Issue:5 Topics: Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Ethics, Research; Humans; Isoxazoles; Lactones; Pyrazoles; Sulfonamides; Sulfones	2005
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:3 Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2	2006
Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rheumatology (Oxford, England), 2006, Volume: 45, Issue:7 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Costs; Drug Prescriptions; Female; Health Care Costs; Humans; Lactones; Male; Musculoskeletal Diseases; Pyrazoles; Quebec; Retrospective Studies; Sulfonamides; Sulfones	2006
Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? Arthritis and rheumatism, 2006, Feb-15, Volume: 55, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Costs and Cost Analysis; Cyclooxygenase 2 Inhibitors; Drug Costs; Drug Therapy, Combination; Drug Utilization Review; Female; Humans; Lactones; Male; Osteoarthritis; Product Surveillance, Postmarketing; Pyrazoles; Quebec; Retrospective Studies; Sulfonamides; Sulfones	2006
Ocular adverse effects associated with cyclooxygenase-2 inhibitors. Archives of ophthalmology (Chicago, Ill. : 1960), 2006, Volume: 124, Issue:2 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Conjunctivitis; Cyclooxygenase 2 Inhibitors; Etodolac; Humans; Isoxazoles; Lactones; Middle Aged; Pyrazoles; Sulfonamides; Sulfones; Vision Disorders	2006
[Pseudoporphyria and coxib]. Annales de dermatologie et de venereologie, 2006, Volume: 133, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Celecoxib; Cyclooxygenase Inhibitors; Diagnosis, Differential; Drug Eruptions; Female; Guillain-Barre Syndrome; Humans; Lactones; Middle Aged; Porphyrias; Pyrazoles; Skin; Sulfonamides; Sulfones	2006
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug safety, 2006, Volume: 29, Issue:3 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Humans; Insurance, Pharmaceutical Services; Ischemic Attack, Transient; Lactones; Male; Meloxicam; Middle Aged; Myocardial Infarction; National Health Programs; Proportional Hazards Models; Pyrazoles; Risk Assessment; Stroke; Sulfonamides; Sulfones; Taiwan; Thiazines; Thiazoles; Time Factors	2006
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks. Harvard health letter, 2005, Volume: 30, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
[Intestinal side effects of COX-2 inhibitors]. Ugeskrift for laeger, 2006, Mar-27, Volume: 168, Issue:13 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colonic Diseases; Colonic Pouches; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diarrhea; Etodolac; Female; Humans; Ileostomy; Intestinal Obstruction; Intestinal Perforation; Lactones; Middle Aged; Pyrazoles; Sigmoid Diseases; Sulfonamides; Sulfones; Ulcer	2006
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, May-23, Volume: 174, Issue:11 Topics: Age Factors; Aged; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Humans; Lactones; Myocardial Infarction; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Time Factors	2006
Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats. Drug metabolism and disposition: the biological fate of chemicals, 2006, Volume: 34, Issue:8 Topics: Animals; Aorta, Thoracic; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2 Inhibitors; Elastin; Lactones; Male; Protein Binding; Pyrazoles; Pyrroles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Tissue Distribution	2006
Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor. European journal of pharmacology, 2006, Jun-06, Volume: 539, Issue:1-2 Topics: Animals; Brain; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Edema; Fever; Hindlimb; Indoleacetic Acids; Lactones; Lipopolysaccharides; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Tissue Distribution	2006
Celecoxib shown effective in preventing colon polyps. Journal of the National Cancer Institute, 2006, May-17, Volume: 98, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Colonic Polyps; Cyclooxygenase Inhibitors; Humans; Lactones; Multicenter Studies as Topic; Myocardial Infarction; National Institutes of Health (U.S.); Pyrazoles; Randomized Controlled Trials as Topic; Research Support as Topic; Stroke; Sulfonamides; Sulfones; United States	2006
Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke, 2006, Volume: 37, Issue:7 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dose-Response Relationship, Drug; Etoricoxib; Female; Humans; Lactones; Logistic Models; Male; Medical Records Systems, Computerized; Middle Aged; Odds Ratio; Pyrazoles; Pyridines; Sulfonamides; Sulfones; United Kingdom	2006
Tumour necrosis factor-alpha blockers: potential limitations in the management of advanced endometriosis? A case report. Human reproduction (Oxford, England), 2006, Volume: 21, Issue:9 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Endometriosis; Endometrium; Etanercept; Female; Humans; Immunoglobulin G; Infertility, Female; Lactones; Laparoscopy; Prednisone; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides; Sulfones; Tumor Necrosis Factor-alpha	2006
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation, 2006, Jun-27, Volume: 113, Issue:25 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Denmark; Diclofenac; Dose-Response Relationship, Drug; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Patient Readmission; Proportional Hazards Models; Pyrazoles; Recurrence; Registries; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones	2006
Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. Journal of cardiovascular pharmacology, 2006, Volume: 47 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cholesterol, LDL; Cyclooxygenase 2 Inhibitors; Heart; Humans; Lactones; Lipids; Membrane Lipids; Myocardium; Oxidation-Reduction; Phospholipids; Pyrazoles; Sulfonamides; Sulfones; Xanthophylls	2006
Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & medicinal chemistry letters, 2006, Sep-01, Volume: 16, Issue:17 Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Lactones; Molecular Structure; Pyrazoles; Rats; Solubility; Stomach; Sulfonamides; Sulfones; Water	2006
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug safety, 2006, Volume: 29, Issue:7 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Naproxen; Pyrazoles; Sulfonamides; Sulfones; Time Factors; United States; Veterans	2006
Simultaneous determination of celecoxib, meloxicam, and rofecoxib using capillary electrophoresis with surfactant and application in drug formulations. Journal of separation science, 2006, Volume: 29, Issue:7 Topics: Celecoxib; Chemistry, Pharmaceutical; Cyclooxygenase 2 Inhibitors; Electrophoresis, Capillary; Humans; Hydrogen-Ion Concentration; Lactones; Meloxicam; Molecular Structure; Pyrazoles; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Sulfones; Surface-Active Agents; Thiazines; Thiazoles	2006
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart (British Cardiac Society), 2007, Volume: 93, Issue:2 Topics: Aged; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2 Inhibitors; Female; Humans; Lactones; Logistic Models; Male; Myocardial Infarction; Pyrazoles; Recurrence; Risk; Sulfonamides; Sulfones	2007
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug safety, 2006, Volume: 29, Issue:8 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Prescriptions; England; Etoricoxib; Female; Humans; Incidence; Lactones; Male; Middle Aged; Pyrazoles; Pyridines; Research Design; Retrospective Studies; Skin; Stevens-Johnson Syndrome; Sulfonamides; Sulfones; Surveys and Questionnaires	2006
The COX-2 inhibitors--an update. American heart journal, 2006, Volume: 152, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2006
Are there differences in the renal effects of selective cyclo-oxygenase 2 inhibitors? Nature clinical practice. Nephrology, 2006, Volume: 2, Issue:4 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Kidney; Lactones; Pyrazoles; Sulfonamides; Sulfones	2006
Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochemical and biophysical research communications, 2006, Oct-20, Volume: 349, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Celecoxib; Cell Line; Endothelium, Vascular; Gene Expression Regulation; Heart Diseases; Humans; Lactones; Muscle, Smooth, Vascular; Pyrazoles; Sulfonamides; Sulfones; Thromboplastin; Thrombosis; Transcription, Genetic; Tumor Necrosis Factor-alpha	2006
How specific are "target-specific" drugs? Celecoxib as a case in point. Molecular interventions, 2006, Volume: 6, Issue:4 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Isoxazoles; Lactones; Molecular Structure; Protein Binding; Pyrazoles; Sulfonamides; Sulfones	2006
[Cyclooxygenase inhibitors: a never ending story?]. Giornale italiano di cardiologia (2006), 2006, Volume: 7, Issue:7 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Europe; Humans; Isoxazoles; Italy; Lactones; Liability, Legal; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; Pyrazoles; Sulfonamides; Sulfones; Texas; United States; United States Food and Drug Administration	2006
Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clinical therapeutics, 2006, Volume: 28, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Odds Ratio; Pyrazoles; Safety; Sulfonamides; Sulfones; Sulindac	2006
[A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor]. The Korean journal of hepatology, 2006, Volume: 12, Issue:3 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Lactones; Liver Neoplasms; Pyrazoles; Sulfonamides; Sulfones	2006
Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clinical and experimental pharmacology & physiology, 2006, Volume: 33, Issue:10 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Kidney; Lactones; Male; Meloxicam; Placebos; Potassium; Pyrazoles; Rats; Rats, Sprague-Dawley; Sodium; Sulfonamides; Sulfones; Thiazines; Thiazoles	2006
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects. Thrombosis and haemostasis, 2006, Volume: 96, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Animals; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Approval; Drug Evaluation, Preclinical; Etoricoxib; European Union; Humans; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboembolism	2006
Inhibition of prostaglandin F(2alpha) by selective cyclooxygenase 2 inhibitors accounts for reduced rat leukocyte migration. Inflammation, 2005, Volume: 29, Issue:4-6 Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Female; Indomethacin; Injections, Intraperitoneal; Lactones; Lipopolysaccharides; Neutrophil Infiltration; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Time Factors	2005
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis and rheumatism, 2006, Volume: 54, Issue:11 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Lactones; Male; Multivariate Analysis; Myocardial Infarction; Naproxen; Pyrazoles; Rheumatic Diseases; Risk Assessment; Risk Factors; Sulfonamides; Sulfones	2006
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Prescriptions; Drug Utilization; Female; Hospitalization; Humans; Ibuprofen; Lactones; Male; Myocardial Infarction; Product Surveillance, Postmarketing; Proportional Hazards Models; Pyrazoles; Quebec; Retrospective Studies; Sex Factors; Sulfonamides; Sulfones	2007
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen. Harvard heart letter : from Harvard Medical School, 2006, Volume: 17, Issue:2 Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2006
Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory? Gastroenterology, 2006, Volume: 131, Issue:6 Topics: Adenoma; Celecoxib; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Lactones; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Time Factors	2006
The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities. Chemistry & biodiversity, 2005, Volume: 2, Issue:7 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Lactones; Models, Molecular; Molecular Structure; Nitric Oxide Donors; Oxadiazoles; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; Vasodilator Agents	2005
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation, 2007, Jan-23, Volume: 115, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Ventricular Remodeling	2007
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Lactones; Male; Myocardial Infarction; Naproxen; Pyrazoles; Quebec; Retrospective Studies; Risk Assessment; Sulfonamides; Sulfones	2007
Cyclooxygenase-2 inhibition increases gastric tone and delays gastric emptying in rats. Neurogastroenterology and motility, 2007, Volume: 19, Issue:3 Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Gastric Emptying; Gastric Mucosa; Indomethacin; Isoxazoles; Ketorolac; Lactones; Male; Muscle, Smooth; Pyrazoles; Rats; Rats, Wistar; Stomach; Sulfonamides; Sulfones	2007
Coxibs: can this class of drugs survive? Vascular health and risk management, 2005, Volume: 1, Issue:1 Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2005
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:8 Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Female; France; Gastrointestinal Diseases; Health Surveys; Humans; Lactones; Logistic Models; Male; Middle Aged; Patient Selection; Pharmacoepidemiology; Practice Patterns, Physicians'; Prospective Studies; Pyrazoles; Risk Factors; Sex Factors; Sulfonamides; Sulfones	2007
Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect? Arthritis and rheumatism, 2007, Apr-15, Volume: 57, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Heart Failure; Humans; Indomethacin; Lactones; Logistic Models; Male; Odds Ratio; Patient Readmission; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2007
Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition. Molecular vision, 2007, Apr-30, Volume: 13 Topics: Animals; Apoptosis; Biomarkers; Cataract; Celecoxib; Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dog Diseases; Dogs; Epithelial Cells; In Vitro Techniques; Lactones; Lens, Crystalline; Mesoderm; Pyrazoles; Sulfonamides; Sulfones; Up-Regulation	2007
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. International journal of biological sciences, 2007, Jun-13, Volume: 3, Issue:5 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Celecoxib; Chemoprevention; Cyclooxygenase 2 Inhibitors; Female; Humans; Ibuprofen; Lactones; Logistic Models; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Ohio; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones	2007
The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Cardiovascular toxicology, 2007, Volume: 7, Issue:1 Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Death; Cell Line; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fluorescent Dyes; Humans; Iloprost; K562 Cells; L-Lactate Dehydrogenase; Lactones; Microscopy, Fluorescence; Myocytes, Cardiac; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones	2007
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:3 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Fluorouracil; Humans; Lactones; Pyrazoles; Stomach Neoplasms; Sulfonamides; Sulfones	2007
The pain game. Nature, 2007, Jul-26, Volume: 448, Issue:7152 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Drug Approval; Humans; Lactones; Mice; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2007
Chemoprevention with special reference to inherited colorectal cancer. Familial cancer, 2008, Volume: 7, Issue:1 Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Ascorbic Acid; Celecoxib; Chemoprevention; Clinical Trials as Topic; Colorectal Neoplasms; Curcumin; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Eflornithine; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Sulindac; Vitamins	2008
Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. Pharmacological research, 2007, Volume: 56, Issue:3 Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Barium; Calcium Channel Blockers; Calcium Channels, L-Type; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Isoquinolines; Lactones; Membrane Potentials; Nifedipine; Nitrobenzenes; omega-Agatoxin IVA; omega-Conotoxin GVIA; PC12 Cells; Pheochromocytoma; Protein Kinase Inhibitors; Pyrazoles; Rats; Spider Venoms; Sulfonamides; Sulfones	2007
The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PloS one, 2007, Sep-05, Volume: 2, Issue:9 Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Population Surveillance; Pyrazoles; Sulfonamides; Sulfones	2007
Orthodontic tooth movement after different coxib therapies. European journal of orthodontics, 2007, Volume: 29, Issue:6 Topics: Alveolar Process; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cephalometry; Cyclooxygenase 2 Inhibitors; Gingiva; Isoxazoles; Lactones; Male; Molar; Orthodontic Wires; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Sulfones; Time Factors; Tooth Movement Techniques	2007
Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:12 Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Celecoxib; Competitive Medical Plans; Health Maintenance Organizations; Humans; Insurance Claim Review; Lactones; Medical Records Systems, Computerized; Myocardial Infarction; Naproxen; Population Surveillance; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Retrospective Studies; Rhabdomyolysis; Sulfonamides; Sulfones; Time Factors; Treatment Outcome; United States	2007
Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Molecular carcinogenesis, 2008, Volume: 47, Issue:7 Topics: Apoptosis; Celecoxib; Cell Adhesion Molecules; Cell Proliferation; Colonic Neoplasms; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 2; Cyclin D1; Cyclooxygenase Inhibitors; Enzyme Activation; Humans; Indomethacin; Lactones; Meclofenamic Acid; Microfilament Proteins; Mitogen-Activated Protein Kinase 8; Phosphoproteins; Phosphorylation; Pyrazoles; Sulfonamides; Sulfones; Tumor Cells, Cultured	2008
Use of cox-2 inhibitors in patients with retinal venous occlusive disease. Retina (Philadelphia, Pa.), 2008, Volume: 28, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Utilization; Female; Humans; Isoxazoles; Lactones; Male; Middle Aged; Prevalence; Pyrazoles; Retinal Vein Occlusion; Retrospective Studies; Sulfonamides; Sulfones	2008
Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance? Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:5 Topics: Adult; Aged; Causality; Celecoxib; Computer Simulation; Cyclooxygenase 2 Inhibitors; Databases, Factual; Epidemiologic Methods; Female; Gastrointestinal Diseases; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Patient Selection; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones	2008
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Follow-Up Studies; Humans; Isoxazoles; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Osteoarthritis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; United States	2008
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. British journal of clinical pharmacology, 2008, Volume: 65, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Heart Failure; Hospitalization; Humans; Lactones; Male; Pyrazoles; Recurrence; Risk Factors; Statistics as Topic; Sulfonamides; Sulfones	2008
Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? European journal of clinical pharmacology, 2008, Volume: 64, Issue:8 Topics: Adverse Drug Reaction Reporting Systems; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; France; Humans; Lactones; Odds Ratio; Pyrazoles; Sulfonamides; Sulfones; Thrombosis	2008
The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Drug Utilization Review; Drugs, Generic; Etodolac; Humans; Incidence; Lactones; Male; Medical Records; Middle Aged; Myocardial Infarction; Naproxen; Prevalence; Prognosis; Pyrazoles; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Texas; Veterans	2008
NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. Drug safety, 2008, Volume: 31, Issue:11 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diabetes Complications; Diuretics; Drug Interactions; Female; Humans; Kidney Diseases; Lactones; Male; Pyrazoles; Renin-Angiotensin System; Risk; Sulfonamides; Sulfones	2008
Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis and rheumatism, 2009, Jan-15, Volume: 61, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antirheumatic Agents; Biopsy; Celecoxib; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney; Lactones; Longitudinal Studies; Lupus Erythematosus, Systemic; Male; Middle Aged; Outcome Assessment, Health Care; Prednisone; Pyrazoles; Severity of Illness Index; Sulfonamides; Sulfones; Young Adult	2009
Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Pharmacotherapy, 2009, Volume: 29, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gastrointestinal Diseases; Hospitalization; Humans; Lactones; Logistic Models; Male; Middle Aged; Pyrazoles; Risk; Saskatchewan; Sulfonamides; Sulfones; Young Adult	2009
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Follow-Up Studies; Hospitalization; Humans; Ibuprofen; Incidence; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Outpatients; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; Tennessee	2009
Celecoxib activates PI-3K/Akt and mitochondrial redox signaling to enhance heme oxygenase-1-mediated anti-inflammatory activity in vascular endothelium. Free radical biology & medicine, 2010, Apr-15, Volume: 48, Issue:8 Topics: Acetylcysteine; Celecoxib; Chromones; Endothelial Cells; Enzyme Induction; Heme Oxygenase-1; Humans; Lactones; Morpholines; NF-E2-Related Factor 2; Oxidation-Reduction; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Protoporphyrins; Pyrazoles; Signal Transduction; Sulfonamides; Sulfones; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1	2010
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan. Clinical therapeutics, 2009, Volume: 31, Issue:11 Topics: Aged; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Drug Utilization; Female; Humans; Insurance Claim Review; Lactones; Male; Middle Aged; National Health Programs; Patients; Physicians; Practice Patterns, Physicians'; Prescriptions; Product Recalls and Withdrawals; Pyrazoles; Regression Analysis; Retrospective Studies; Sulfonamides; Sulfones; Taiwan	2009
Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study. European journal of clinical pharmacology, 2010, Volume: 66, Issue:6 Topics: Angina, Unstable; Celecoxib; Cerebral Infarction; Cyclooxygenase 2 Inhibitors; Databases, Factual; Death, Sudden; Female; Humans; Iceland; Incidence; Lactones; Male; Myocardial Infarction; Odds Ratio; Pyrazoles; Registries; Risk Factors; Sulfonamides; Sulfones; Thromboembolism; Young Adult	2010
Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone. Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:9 Topics: Aldosterone; Angiotensin II; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Cardiomegaly; Celecoxib; Collagen; Cyclooxygenase 2 Inhibitors; Female; Fibroblasts; Fibrosis; Heart; Hep G2 Cells; Hepatocytes; Humans; Lactones; Male; Myocardium; Myocytes, Cardiac; Naproxen; Pyrazoles; Rats; Renin-Angiotensin System; Sulfonamides; Sulfones; Vasoconstrictor Agents	2010
Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:1 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Humans; Incidence; Isoxazoles; Lactones; Logistic Models; Middle Aged; Odds Ratio; Pyrazoles; Risk; Sulfonamides; Sulfones	2011
Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing. Research in social & administrative pharmacy : RSAP, 2010, Volume: 6, Issue:3 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Costs; Education, Medical, Continuing; Female; Humans; Lactones; Male; Middle Aged; Nova Scotia; Physicians; Practice Patterns, Physicians'; Pyrazoles; Rural Health Services; Sex Factors; Sulfonamides; Sulfones; Urban Health Services	2010
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3. Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:5 Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis	2010
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. European heart journal, 2012, Volume: 33, Issue:15 Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Female; Heart Failure; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrazoles; Safety-Based Drug Withdrawals; Stroke; Sulfonamides; Sulfones; Sweden	2012
Concordance with guideline recommendations: previous and more recent nonsteroidal anti-inflammatory drug prescriptions in Quebec, Canada. Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:4 Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Databases, Factual; Female; Guideline Adherence; Humans; Lactones; Logistic Models; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Quebec; Risk Factors; Safety-Based Drug Withdrawals; Sex Factors; Socioeconomic Factors; Sulfonamides; Sulfones; Time Factors	2012
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. Journal of pediatric surgery, 2012, Volume: 47, Issue:6 Topics: Basement Membrane; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Lactones; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Pyrazoles; Sarcoma, Ewing; Sulfonamides; Sulfones	2012
Assessment of radioligands for PET imaging of cyclooxygenase-2 in an ischemic neuronal injury model. Brain research, 2013, Oct-02, Volume: 1533 Topics: Animals; Antibodies; Brain; Brain Ischemia; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2; Disease Models, Animal; Lactones; Male; Mice; Mice, Inbred C57BL; Positron-Emission Tomography; Pyrazoles; Sulfonamides; Sulfones	2013
Toward a Better Understanding of the Physical Stability of Amorphous Anti-Inflammatory Agents: The Roles of Molecular Mobility and Molecular Interaction Patterns. Molecular pharmaceutics, 2015, Oct-05, Volume: 12, Issue:10 Topics: Anti-Inflammatory Agents; Celecoxib; Crystallization; Dielectric Spectroscopy; Drug Stability; Etoricoxib; Lactones; Pyridines; Sulfones	2015
Actions following adverse drug events - how do these influence uptake and utilisation of newer and/or similar medications? BMC health services research, 2015, Nov-06, Volume: 15 Topics: Aged; Australia; Bone Density Conservation Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lactones; Medication Adherence; Meloxicam; Osteoporosis; Sulfones; Thiazines; Thiazoles	2015
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria. Toxicology in vitro : an international journal published in association with BIBRA, 2016, Volume: 32 Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones	2016
Crystal structure of rofecoxib bound to human cyclooxygenase-2. Acta crystallographica. Section F, Structural biology communications, 2016, 10-01, Volume: 72, Issue:Pt 10 Topics: Amino Acid Motifs; Binding Sites; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Gene Expression; Humans; Kinetics; Lactones; Models, Molecular; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Recombinant Proteins; Safety-Based Drug Withdrawals; Substrate Specificity; Sulfones	2016
COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2017, Volume: 65, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biological Transport; Celecoxib; Cell Adhesion; Cell Line; Cholesterol; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Endothelial Cells; Foam Cells; Gene Expression Regulation; Gene Silencing; Humans; Inflammation; Lactones; Lipoproteins, LDL; Macrophages; Models, Biological; Monocytes; Receptors, Scavenger; Sulfones	2017
The wider role of regulatory scientists. BMJ (Clinical research ed.), 2017, 04-27, Volume: 357 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Data Accuracy; Decision Making; Ethics, Research; Humans; Lactones; Paroxetine; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Societies, Scientific; Sulfones; Treatment Outcome; United States; United States Food and Drug Administration	2017
NSAIDs and cardiac arrest: Non-steroidal anti-inflammatory drug use is associated with increased risk of Out-of-hospital Cardiac Arrest: A nationwide Case-Time-Control study. European heart journal, 2017, 06-14, Volume: 38, Issue:23 Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Denmark; Humans; Ibuprofen; Lactones; Naproxen; Out-of-Hospital Cardiac Arrest; Risk Factors; Sulfones	2017
Drug-Disease Interaction: Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid. Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arthritis, Experimental; Celecoxib; Cytochrome P-450 Enzyme System; Heart; Hydroxyeicosatetraenoic Acids; Inflammation; Kidney; Lactones; Male; Meloxicam; Rats; Rats, Sprague-Dawley; Sulfones; Thiazines; Thiazoles	2018
Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat. Cells, 2019, 03-15, Volume: 8, Issue:3 Topics: Animals; Bacteria; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dysbiosis; Gastric Mucosa; Gastrointestinal Microbiome; Intestine, Small; Lactones; Male; Microbial Sensitivity Tests; Rats, Wistar; Sulfones; Time Factors	2019
Identification of Potential COX-2 Inhibitors for the Treatment of Inflammatory Diseases Using Molecular Modeling Approaches. Molecules (Basel, Switzerland), 2020, Sep-12, Volume: 25, Issue:18 Topics: Animals; Binding Sites; Caco-2 Cells; Celecoxib; Cyclooxygenase 2 Inhibitors; Dogs; Drug Evaluation, Preclinical; Humans; Inflammation; Inhibitory Concentration 50; Lactones; Madin Darby Canine Kidney Cells; Molecular Docking Simulation; Molecular Structure; Permeability; Protein Binding; Quantitative Structure-Activity Relationship; Regression Analysis; Software; Sulfones	2020
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells. BMC cancer, 2021, May-03, Volume: 21, Issue:1 Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway	2021